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The World Health Organization published in 2004 a bulletin addressing the gap 
between research, technology, and its implementation in the health systems of different 
countries (Haines, Kuruvilla, & Borchert, 2004).  Among the barriers described for the 
implementation of new knowledge in the medical practice is the lack of connection 
between research results and policy makers. This happens in different subfields within 
the medical field. The focus of this project is to analyze the differences in implementation 
of radionuclide therapy technology between the EU and the US. The hypothesis is that 
this technology has been implemented in the EU earlier and more often than in the US, 
and that this variation can be connected to the differences in the policies relevant to 
nuclear medicine.  
Nuclear medicine is a unique field because of the way radioactive material is used 
to create diagnostic images and treat illnesses (mostly cancer). Although radiation is used 
every day in radiotherapy and radiology, the main difference between these two fields 
and nuclear medicine is the type of radiation used. Radiotherapy and radiology use closed 
sources of radiation, or particle accelerators that produce radiation, while nuclear 
medicine uses open sources of radiation that are injected into the patient’s body. This is 
an important difference because the accelerators used in radiotherapy and radiology can 
be turned on and off unlike the open sources of radiation used for nuclear medicine. If not 
handled properly, open sources of radiation may cause radiation contamination. 
Additionally, the radioactive material must be supplied on a daily basis. With nuclear 
medicine is possible to create diagnostic images of the body, and to record bodily 




illnesses, such as some types of cancer, in a targeted manner. This is possible because the 
radioactive material is “connected” with a chemical compound (or drug) that carries the 
radioactive atoms to a desired location in the body; this is called targeted therapy. It is 
also possible to inject the radioactive material directly into the organ or region of interest. 
The targeted therapy and injected techniques are two processes that are part of 
radionuclide therapy technology. 
In order to check the status of the implementation of radionuclide therapy I used 
the practice guidelines published on the websites of the European Association of Nuclear 
Medicine (EANM) and the Society of Nuclear Medicine (SNM) in the US. Assuming that 
the practice guidelines are evidence of well-established and implemented techniques in 
the regions, these documents were evaluated according to their content and publication 
date. The content analysis was focused on the type of practices described: diagnostic, 
general, or therapy, as well as the type of radioactive material (or radioactive isotopes) 
used in such practices. The practice guidelines evaluation was done in Nvivo, a text 
analysis software. In addition to the analysis of practice guidelines, a bibliometric 
analysis of four databases (Pubmed, Medline, Biosis, and ISI Web of Science) was 
conducted in four databases. The keywords used for the search were (“radionuclide 
therapy” AND case AND report) OR (radioinmunotherapy AND case AND report). Case 
reports are publications that expose the day-to-day practice of physicians, and allow 
medical personnel to take a detail look into a specific case. The records from these 
sources were analyzed in Vantage Point, a bibliometric analysis software. From the 
policy landscape, three main types of policies were studied in relation to the practice of 




second, the policies related to the approval of radiopharmaceuticals in the different drug 
administration entities; and finally, the policies concerning the production of radionuclide 
therapies in the two regions. 
The main finding of this project is that Europe and US have different policy 
approaches that affect, directly or indirectly, the nuclear medicine field. The main 
differences are in the standards of education for nuclear medicine specialist that is 
divided between radiologist and nuclear medicine specialists in the US; the production of 
radioactive material, which is commercially supplied by a very few reactors in the world, 
none of them in the US; and the drug administration institutions, which have very 
different approaches approving new drugs. Aditionally, Europe has implemented more 
radionuclide therapy technologies than US. 
 From the practice guidelines analysis, it was evident that the US started 
publishing guidelines for nuclear medicine several years before Europe. The US 
published its first guideline in 1994, while the EU’s first guideline was published in 2000. 
However, as of July 2013, the European association had published more guidelines with 
54 unique ones versus 49 from the US. EU also leads in the number of guidelines in 
regards to therapy, with 13 versus 2 from the US. Additionally, there is more variety in 
the radioisotopes used in therapy than the ones in diagnostics, and all the radioisotopes 
are mentioned in the European guidelines, while the US doesn’t have guidelines that 
mention Lu-177, Re-186, and Y-90 isotopes. 
 From the bilbiometric analysis it was evident that Europe had published case 
reports for more time and more frequently than the US regarding radionuclide therapy. 




the first case report in the US. Additionally, the US has only 10 publications that match 
the keywords while the EU has 37. In conclusion, the EU has more practice guidelines on 
radionuclide therapies regarding more types of illnesses and more radioisotopes, and 
Europeans have published more case reports on these therapies, which indicates that the 
EU has implemented radionuclide therapy technology more fully than has the US. 
The differences in the policies and standards in education for Nuclear Medicine 
may influence this difference, because EU has a more standardized education and a more 
unified professional field than US. While the EU has a proposed syllabus for nuclear 
medicine practitioners, medical physicists, and radiopharmacists, in the US the education 
is neither standardized nor unified. Two different boards can certify physicians 
specializing in nuclear medicine: the American Board of Radiology and The American 
Board of Nuclear Medicine. The first one does a Nuclear Radiology certification for 
which the physicians are not required or allowed to conduct radionuclide therapies, while 
the American Board of Nuclear Medicine requires more nuclear medicine training and 
involves diagnostics and therapy. These differences are important in the implementation 
of radionuclide therapy techniques, because not all the nuclear medicine physicians in the 
US are trained on this aspect or allowed to practice it. For that reason a fraction of the 
professionals may not be interested or informed about these techniques, leaving the field 
of nuclear medicine in the US behind its EU counterpart. 
The policies that involve the production of radioisotopes and the market for this 
good deeply affects the status of the field in both regions. Since most of the radionuclide 
materials for therapies are produced in nuclear reactors, this is a very complex topic. 




frequently associated with medicine. The precautionary approach that some regions apply 
to this topic may affect the availability of the radioisotopes in local markets. The EU has 
more nuclear reactors capable of the production of materials for radionuclide therapies, 
while the production of radioisotopes in the US is less and it focused on research. 
Therefore, the EU has a more stable and reliable supply of radioisotopes, which allows 
them to use the technology in everyday practice. 
Finally, the drug administration entities seem to differ in the clarity of their 
procedures for the approval of radiopharmaceuticals. The EU tools for approval are clear 
and easy to find, which may encourage European researchers to work on new 
radiopharmaceuticals and to carry their findings to the application level. The European 
Medicines Agency has a Radiopharmaceutical Drafting Group that supports the creation 
and approval of radiopharmaceuticals. In addition, one of the practice guidelines from the 
European Association of Nuclear Medicine (EANM) is about the approval of new drugs. 
This is not replicated in the US; although the Food and Drug Administration (FDA) has a 
special group that works with radiation therapies and devices, there are no references to a 
group that relates to radiopharmaceuticals, or the information is not as easy to find. It also 
looks like the Society of Nuclear Medicine (SNM) is focusing more on research and 
approval of Positron Emission Tomography (PET) radiopharmaceuticals than on therapy 
based ones. This is understandable since the radioactive material for PET images is 
produced in cyclotrons available at many clinics and hospitals around the world. 
In conclusion, nuclear medicine is a very diverse field that is capable of important 
contributions to medicine. However, the radioactive nature of the material needed for the 




drugs. The availability of the drug and the personnel trained in these matters are the most 
important factors for the successful use of this technology. Although the US and the EU 
have been collaborating more and more in the creation of standardized procedures for 
nuclear medicine, it is evident that the EU has more experience in the day to day 
application of the technology, and the technology is also more accessible in the EU by the 
physicians interested in it. A trained and informed group of professionals can raise 
awareness in the public and influence the policy making by monitoring agencies to create 
clearer paths for drug approvals, and pushing for laws that approve the research and 




CHAPTER 1- INTRODUCTION 
The World Health Organization published in 2004 a bulletin addressing the gap 
between research, technology, and its implementation in the health systems of different 
countries (Haines et al., 2004).  Among the barriers described in this bulletin is the lack 
of connection between research results and different policy makers. This disconnect is 
one of the biggest problems of technology transfer in many different fields, but it is 
especially important for healthcare due to its potential for improving the quality of 
people’s lives.  
The differences in policies that result in different time transfer for implementation 
of new technologies may affect some medical fields more than others, and the time may 
depend on the demand for the device/drug, the availability of the resources to make it, 
and the knowledge of the practitioners and policy makers, among other factors. A field 
that is potentially affected by local policies is Nuclear Medicine (NM), and particularly 
the subfield of radionuclide therapies. The radioactive nature of the materials that are 
needed in this medical field brings to the table more regulatory agencies and policies, 
both local and international, which may cause a greater variation in the implementation 
time around the world. NM also requires numerous professionals with very specific and 
specialized training, as well as specialized technology. 
The main objective of this project is to understand how, if at all, the differences in 
policies affect the time of implementation and the techniques used for radionuclide 
therapies between the European Union (EU) and United States (US). The hypothesis is 
that this technology has been implemented in the EU earlier and with more variations 




relevant to nuclear medicine. Differences in policies between the EU and the US have 
been studied in other fields; however, the specific relation among the various types of 
policies that surround nuclear medicine and their effects on the implementation of these 
techniques is not clear. There are three main questions in this project which inform the 
primary objective: 1) Are radionuclide therapies implemented more in the EU than in the 
US? 2) What differences are there in the policies relevant to nuclear medicine between 
the US and the EU? 3) To what extent, if at all, can the differences in policies explain 
differences in the time of implementation of radionuclide therapies? 4) What other factors 
might explain these differences in the time of implementation?  
Even though the adoption and implementation of new technology is important for 
the advance of health care systems, in some cases, such as in information and 
communication technology, there are good reasons for the delay of the implementation; 
for example, the irreversibility of technology application (Christensen & Remler, 2009). 
Nevertheless, the same delay in the pharmaceutical and medical devices fields may cost 
more money and wellbeing to patients due to the lack of access to the newest and most 
effective treatments and diagnosis procedures (Bell, 1983; Kaplan et al., 2004; Kereiakes 
& Willerson, 2004). This is especially evident in the differences between US’s and the 
EU countries’ health systems. The way these systems are design allow some drugs and 
devices to be available considerably earlier in the EU countries than in the US because 
the US requires studies on safety and effectiveness while EU only requires the first 
(Kaplan et al., 2004). This variation in implementation may be critical for many human 
lives in the US that need to wait for years for the medical trials to prove effectiveness. At 




effective because the early implementation of drugs is done without the effectiveness test 
that the US requires.  
Nuclear Medicine is an interesting field because of the nature of the field itself. 
Radiation has been use in medicine since Wilhelm Conrad Röntgen discovered “X-rays” 
in 1895; this technology was implemented in medicine very fast because it is a very 
useful diagnostic tool. Today, almost every clinic has an “X-ray” machine in any of its 
varieties, and many physicians specialize in radiology, which includes the reading of the 
“X-ray” images. NM is considered as part of the radiology field in the US, but is an 
independent field in other parts of the world. There are four main reasons why NM is 
different from radiology. First, the nature of the radiation itself makes the approach 
different. NM uses “open radiation sources,” which use radioactive material in the form 
of a liquid or pills that are not necessarily contained or encapsulated, and is perceived as 
more hazardous, requiring more stringent safety routines and practices. Second, 
depending on the complexity of the procedures done in the nuclear medicine facility, it 
requires more trained professionals, such as a pharmaceutical chemist to prepare the 
radioactive materials for use. Third, NM requires a constant supply of radioactive 
material. Finally, NM has the potential to serve as a diagnostic tool as radiology does, but 
NM has the potential to do diagnostic images down to the molecular level, and to be use 
in therapies for cancer and other diseases. Although the implementation of the newest 
advance in diagnostic nuclear medicine, the positron emission tomography (PET) scan, 
seems very popular in the US and the EU, the case is not the same for the radionuclide 
therapies or treatment technologies. NM has been used for radionuclide therapies since 




based on the ability to treat targeted regions and cells in the body by linking the radiation 
with a molecule that transports it throughout the body, but it has not evolved as fast as 
other parts of the NM field (A. J. B. McEwan, 2002), and the major advances have not 
been implemented uniformly between regions.  
The word “nuclear” is constantly associated with risk, danger, and fear. It is for 
this reason that it is necessary to talk about risk perception and the precautionary 
principle whenever the words nuclear, radiation, or other synonymous terms appear in the 
discussion. Spencer Weart, an expert in the history of modern physics, describes in the 
first part of his book Nuclear Fear how radiation was, since its discovery, associated with 
something powerful enough to destroy the earth or to keep it safe, providing a continuous 
clean energy supply. Many scientists of the time, as well as artists and writers influenced 
the negative or positive, but powerful, first perceptions that people had about radiation 
(Weart, 1988). 
When radiation was discovered, and with it, its medical applications, people 
started using radiation as a “magic” formula that could solve many medical problems. 
The consequences of radiation over exposure and misuse became evident over time, and 
radiation became associated with health problems such as cancer and mutations. The 
health effects of uncontrolled exposure to radiation, and tragic events such as the Three 
Mile Island reactor meltdown in Pennsylvania in 1979, the explosion of the atomic bomb 
in Hiroshima and Nagasaki in 1945, the meltdown of the reactor in Chernobyl in 1986, 
the Goiana accident of radiation contamination in Brazil in 1987, and the nuclear disaster 





Perception of risk is a topic that has been largely studied by psychologists and 
social scientists. There are many theories about why people perceive risk the way they do 
with respect to a technology. The knowledge theory is one of the most common, and it is 
based in the idea that the perception of risk or safety depends on how much the person 
knows about the topic. Another very common theory is the personality theory, which 
associates the risk taker/risk averse qualities of a person with his or her personality 
characteristics overall. There is also a political theory, which relates controversies, 
interests, and positions of power with risk perception. Finally, the cultural theory, which 
seems very powerful, is based on the idea that our perception of risk is deeply embedded 
among our ideologies, values, and beliefs. Wildavsky and Dake tested these theories to 
find which one is able to predict the person’s risk perception about a technology. They 
found that cultural biases are the strongest predictor of risk perception (Wildasvsky & 
Dake, 1990). This is also confirmed by other studies where the difference in risk 
perception by experts and non-experts in radiation is tested, without finding that 
knowledge can predict the risk perception (the knowledge theory) because in some cases 
experts’ risk perception is higher than the public’s, and in other cases, it is the other way 
around (Freudenberg & Beyer, 2011; Perko, 2013). Something very important in the risk 
perception theories is the type of risk under study; characteristics such as observable or 
not, immediate or delayed effects, and controllable or not, among others, shape the 
perception of different technologies, and place radiation risk in a position of high 
uncertainty. The characteristics of radiation as an uncontrollable, fatal, and observable 




Several authors have studied the differences between the approach to risk between 
the EU and the US. Some think that the EU is more precautionary than the US, others 
think that it is the opposite, and others think that they changed in time with Europe more 
precautionary before 1970, and then US. Testing these three hypotheses, Wiener and 
Rogers studied the cases of beef, hormones, blood donations, and mad cow disease and 
found that the pattern of precaution is more complicated than black or white, and it 
changes with time and type of risk (Wiener & Rogers, 2002). Later, Hammitt et al. 
created a database of over 2000 risks, randomly selected 100, and tested the stringency of 
the regulations in EU and US for these risks in the period from 1970 to 2004. They found 
that neither region could be called more precautionary than the other (Hammitt, Wiener, 
Swedlow, Kall, & Zhou, 2005). This is important for this project because neither of the 
two regions can be defined as more precautionary than the other. 
Assuming that the professional associations of NM in the two regions and the 
practice guidelines that they publish are evidence of the practices in the day to day 
routine, the official practice guidelines from the Society of Nuclear Medicine (SNM) and 
the European Associations of Nuclear Medicine (EANM) would be used, and would 
account for the differences in this field between the US and the EU. I expect to find that 
radionuclide therapy techniques are implemented in the EU more than in the US. The 
practice guidelines can be accessed on the websites of the two organizations, and in most 
cases these are also published in the official journal of each society. In order to compare 
them they were categorized in date of first publication when available, topic, radioactive 
material used, and type of procedure. The text analysis software Nvivo was used to code 




In addition to the practice guidelines, a bibliometric study of case reports was 
used as evidence of implementation of radionuclide therapy techniques in both regions. 
The databases used for the bibliometric search were PubMed, Medline, Biosis Preview 
and ISI Web of Knowledge. The key words used in the search were (“radionuclide 
therapy” AND case AND report) OR (radioinmunotherapy AND case AND report). 
Radioinmunotherapy is a specific type of radionuclide therapy used mainly in patients 
with non-Hodgkins Lymphoma. I selected case report publications because “[i]n 
medicine, a case report provides important and detailed information about an individual 
patient, their symptoms, diagnosis, treatment and the outcome of that treatment. Case 
reports may arise during routine clinical practice and during clinical research studies” 
(CaseDatabase, n.d.), which serves as an evidence of implementation of the technology. 
It is possible that neither the practice guidelines nor the case reports show the 
complete picture of the implementation stage of radionuclide therapies in each region. 
Practice guidelines and case reports take a long time to develop and get published and 
these times may vary between regions, which will not show the real picture of what is 
currently happening in the regions. It is also possible that the practitioners don’t have an 
interest in publishing even if they are implementing and have experiences with these 
technologies. The opposite may happen too; it is possible that there are practice 
guidelines that nobody uses, or case reports on techniques that are implemented in very 
specific groups that don’t represent the regions. There are more direct methods to 
measure implementation of a technique, such as surveys of medical centers and staff, 




in the area. However, all these require a more extensive and expensive study, which is out 
of the scope of this project. 
 The policies that are going to be analyzed in relation with NM are classified in 
three groups:  professional, radioisotope supply, and drug/medical device policies. The 
policy search was done on the web, and was focused on regulations and laws that affected 
NM internationally and in each of the regions. Because there are different levels of 
regulations and agreements that affect NM, the policies were classified as international, 
national and local (in the US some policies are applied only at the state level). As a result 
of differences in the policy fields and their infrequent overlapping (besides in the nuclear 
medicine case) it is not possible to determine clear causal relations between the 
differences in policies and the variations in the implementation of the nuclear medicine 
techniques analyzed here. Additionally there are may differences in policies at different 
levels; for example, there are some professional certifications that in the US are managed 
at the state level while in Europe they are managed at the national or even international 
level. These differences in level, and the connections between regulatory agencies (e.g. 
nuclear regulations and drug development) make it difficult to create causal connections 
or assign the differences to a single explanation. However, the differences in the policy 
context between the regions help to explain the variations in the implementation of some 
nuclear medicine techniques.  
Additionally, during the literature review there was an important observation 
about the “problems” in communication among nuclear medicine practitioners in the US. 
It is possible that the variations in implementation of radionuclide therapy techniques are 




of information among NM professionals in the US seems not to be fluid and/or abundant 
despite efforts of society. This is evident in their publications because research groups are 
conducting clinical trials that other groups are not aware of, which may result in very 
slow flow of patients, expenditure of unnecessary resources, and duplicated efforts 
toward the same goal. Nevertheless, some professionals in this field recognize that there 
is a policy barrier that doesn’t allow them to move forward with clinical trials. They are 
in favor of FDA approvals for different NM therapy techniques in order to be able to 
provide the US’ patients with the same treatments that the EU’s patients have been 
receiving for a while (M. M. Graham & Menda, 2011).  
 Chapter 2 of this document contains a scientific background on what Nuclear 
Medicine is, how radiation and radioactivity have been use in medicine, and why Nuclear 
Medicine is of special interest. It also summarizes the literature review done for this 
project, and provides a background for the following chapters. Chapter 3 explains the 
methods used for the collection of data about the adoption of nuclear medicine, selection 
of unique practice guidelines, and how they were classified by content. It also presents 
the results of the bibliometric analysis. Chapter 4 presents the data analysis on adoption, 
and turns to the possible relationships between features of the policy context and the 
findings with regard to adoption. Finally, Chapter 5 presents the conclusions of the 




CHAPTER 2 – NUCLEAR MEDICINE BACKGROUND 
The Basic Science 
 There are some basic physics concepts that are useful in order to understand the 
complex role of nuclear medicine in the medical world and the challenges it faces. First 
of all, electromagnetic radiation means energy moving through space. There is a broad 
spectrum of radiation types that are the physics principle for great variety of devices; 
some everyday examples are the radio, microwave ovens, and light as shown in Figure 1.  
 Radiation can be classified into two different types: ionizing and non-ionizing 
radiation. Ionizing radiation refers to radiation that is able to interact with the atom. 
These interactions may result in the ionization of an atom, which means that the electric 
charge of an atom changes as a result of the interaction. Atoms tend to be neutral; for this 
reason if their charge changes, they are going to interact with their environment until they 
find equilibrium. If ionizing radiation interacts with an atom that is part of a cell, the 
ionization of this single atom may trigger a huge variety of chemical reactions, which 
may later become biological responses to the radiation. Examples of these biological 
responses are death of the cells, and cell mutations.  
 
Figure 1: Types of Radiation in the Electromagnetic Spectrum 




 Humans can’t sense the presence of ionizing radiation; it doesn’t have a smell or 
taste, and for this reason it is necessary to have special devices or detectors. Ionizing 
radiation detectors are designed in a multitude of ways, but the basic principle is to allow 
the radiation to interact with the material and to record a trace that can be then 
interpreted, such as an electric charge or an image. A detector can create an image and 
reconstruct the path of the radiation, count how much radiation has passed through it, or 
alert us to the presence of radiation. These different types of detectors are used every day 
in medicine, the first one for imaging construction, the second one for control of workers 
exposure to radiation, and the third to control the amount of radiation in the environment 
for safety reasons. 
 We are all exposed to ionizing radiation due to cosmic rays and naturally 
occurring unstable atoms in the earth, but we didn’t know it until in 1896 when Henry 
Becquerel discovered radioactivity when working with uranium salts. Radioactivity is the 
emission of ionizing radiation by unstable atoms or radioisotopes. Atoms are usually 
unstable when their nucleus is so large that it needs to release the extra energy by 
emitting ionizing radiation. There are three types of ionizing radiation that can be emitted 
by this process: alpha (α), beta (β) and gamma (γ). The main difference between these 
types of radiation is the presence and amount of mass, the distance that the ionizing 
radiation can travel through matter, and the amount of energy that it leaves in its 
trajectory. Alpha radiation is massive and can’t go through a sheet of paper, but it can 
deposit a high amount of energy, creating a lot of ionization in a short distance. Beta 
radiation has the same mass as an electron (less than alpha radiation) and it could travel 




millimeters of metal. Finally, gamma radiation doesn’t have mass and can travel long 
distances, produces more spread ionizations, and it is very difficult to stop; in order to 
block gamma radiation it is necessary to use high-density materials such as lead. These 
characteristics are very important when contemplating the practical uses of ionizing 
radiation.  
 
Figure 2: Radiation Particles 
 Source: http://meteorology.lyndonstate.edu/classes/CMS/index.php/particles Retrieved April 20, 
2013 
 Radioactive material is a collection of many radioactive atoms. Radioactive 
materials have very important characteristics besides the type of radiation they emit and 
the energy of the radiation. Once an atom has emitted the extra energy it has in the form 
of radiation, it will not do it again, or it will emit a different type of radiation if the atom 
is too big and has a lot of extra energy. The atom that emits radiation is often known as 
the parent and the resulting atom is a daughter atom. Figure 3 shows the decay scheme of 
Carbon 14, which is known as an isotope used to date archeological elements; Carbon 14 
is the parent in this case, and Nitrogen 14 is the daughter. Nitrogen 14 is stable, but in 




Each of the radioactive atoms emits radioactivity spontaneously. Radioactive material is 
usually characterized by its activity, which is the amount of ionizing radiation emitted per 
second, and varies from sample to sample of the material. Besides activity, the half life of 
a radioactive isotope is a characteristic quantity that is constant for each material, and is 
defined as the time it would take it to decay to half its activity.  
 
Figure 3: Carbon 14 decay 
Source http://cwx.prenhall.com/bookbind/pubbooks/walker2/chapter32/custom1/deluxe-content.html 
retrieved May 5, 2013 
 There are some radioactive atoms that can be found in nature, but most of the 
materials that are used in industry and medicine are by-products of nuclear reactors or 
can be produced by cyclotrons or particle accelerators. Besides the radiation emission of 
unstable atoms, humans have developed different ways to produce radiation. This 
ionizing radiation is known as X-rays and is the product of accelerating electrons against 
a target. The physics of X-rays is the same as that of gamma radiation. X-rays discovered 
in 1895 by William Rögnten. 
 The use of ionizing radiation for peaceful purposes is allowed and should be done 
while trying to keep the exposure to the radiation “as low as reasonably achievable,” 
which is known as the ALARA principle. In order to reduce the exposure there are three 




be reduced to its minimum, the distance from the radiation source should be maximized, 
and proper shielding should exist between the source and the people. 
 Because the misuse of radiation and radioactive materials can lead to terrible 
consequences, in 1953 president Eisenhower presented the “Atoms for Peace” speech in 
front of the 470th Plenary Meeting of the United Nations General Assembly and with it 
gave the basis for the creation of the International Atomic Energy Agency in 1957, whose 
main objective is “… to accelerate and enlarge the contribution of atomic energy to 
peace, health and prosperity throughout the world. It shall ensure, so far as it is able, that 
assistance provided by it or at its request or under its supervision or control is not used in 
such a way as to further any military purpose” (“The Statute of the IAEA,” n.d.). By 
February 2013, 159 countries were part of the IAEA, and these countries join forces to 
develop peaceful uses of radiation and allow IAEA to do inspections to facilities that use 
radioactive material in their countries. As a result of its work, IAEA produces different 
publications and creates standards of practice in medicine, industry and nuclear energy. 
The Use of Radiation in Medicine 
The use of radiation in medicine happened almost immediately after the discovery 
of this phenomenon in nature. It is commonly known that the first radiography ever taken 
was the hand of William Rögnten’s wife. Since the discovery of radioactivity and X-rays, 





Figure 4 First radiography 
Source http://commons.wikimedia.org/wiki/File:First_medical_X-
ray_by_Wilhelm_R%C3%B6ntgen_of_his_wife_Anna_Bertha_Ludwig's_hand_-_18951222.jpg. 
May 5, 2013 
Radiology 
 Radiology is a very important, well established and still controversial branch of 
medicine. Its main objective is to create diagnostic images. It uses X-rays to create 
images of anatomical parts. Almost every hospital has a radiology department, and it is 
there where you can find the X-ray machines, CT scanners, and other imaging devices 
that are not radioactive radiation related such as magnetic resonance and ultrasound.  
 In radiology, radiation is used to create images of the body by placing the 
anatomic part between the radiation source and the detector. Because of the way radiation 
interacts with different types of matter, the detector senses different characteristics of the 
material in between. Bone and soft tissue have different properties; bone can stop X-ray 
while soft tissue can’t. This creates the image of our bones in the detectors; figure 4 is an 




applicability of this tool in medicine was very obvious and since then has advanced from 
the two-dimensional plain images of the Rögnten’s X-ray machine, to the CT possibility 
of having very specific images of thin transversal sections of the body. Figure 5 shows 
the scheme of how an X-ray machine or CT scan works, and figure 6 shows a transversal 
section of someone’s thorax taken by a CT scanner, in the lower right corner is a planar 
front image that locates the transversal cut in the lower part of the lungs.  
 
Figure 5 Scheme of how a X-ray machine or a CT scan works 
Source: http://www.fda.gov/radiation-
emittingproducts/radiationemittingproductsandprocedures/medicalimaging/medicalx-
rays/ucm115318.htm. May 5, 2013 
 
Figure 6 CT scan image of an abdominal cross section 




The physicians that work in this field are in charge of the production of diagnostic 
images that are then use by specialist in other areas. The ionizing radiation in this 
department is well controlled and very safe, since is produced by machines that can be 
turned on and off. Additionally, the devices that produce radiation have plenty of safety 
configurations, and usually, depending on their power, are located in shield rooms with 
safety devices like locked doors, where only the patient remains during the procedure.  
The labor force of a radiology department is composed of the radiologist, the 
technicians, and depending on the complexity of the machines they use and the location, 
an engineer or a medical physicist who frequently visits and checks the department, the 
machines and the procedures. 
Radiotherapy 
The radiotherapy branch of medicine uses radiation to treat cancer. In general, the 
ionizing radiation source is a powerful X-ray machine, and the patient is located at the 
end of the trajectory of the radiation. With this arrangement there is no detector; the 
patient is where the radiation needs to arrive in order to create ionization and kill the 
cancer cells. The first machines used for radiotherapy were discs of radioactive material 
with high energy and long half-lives, which were shielded by a lot of lead in a shield 
room. This technology is not longer preferred because the radioactive material doesn’t 
have an on/off switch, and there are other complications like disposal of the radioactive 
material and loss of control over the radioactive source. This is different from an 
accelerator that produces radiation in the form of X-rays because once the machine is off, 





Figure 7 Scheme of how radiotherapy works 
Source: http://www.patienthealthinternational.com/prostate-
cancer/questio...py?itemId=1620398&nav=yes. May 10, 2013 
The labor force in radiotherapy includes physicians, who usually have a 
specialization in oncology and a sub specialization in radiotherapy, and the technicians. 
For radiotherapy purposes it is necessary to have a medical physicist working full time in 
the service. The reason why more trained personnel is needed in radiotherapy compared 
with radiology is to calculate the doses and arrange the machine’s trajectories over the 
human body, so the patients receive the energy they need to kill the cancer cells in the 
exact location where they need it without hurting other organs. 
There is another therapy called brachytherapy, which places sealed sources of 
radiation in the organs with cancer; it is often used for prostate and cervical cancer. The 
radiation source varies, and depending the country these treatments are considered part of 
radiotherapy or nuclear medicine. The fact that the radiation is in a sealed source is very 
important, and allows the physicians to do very localized “radiotherapies.” 
Nuclear Medicine 
Nuclear Medicine is the branch of medicine that uses unsealed radiation sources 
for the diagnosis and treatment of different pathologies. Unlike the other branches of 




radiation travels through the body, and the images are from outside the patient in the 
detector. 
 
Figure 8 (a) In radiotherapy and X-ray, the radiation is outside the patient. (b) In Nuclear Medicine 
the radiation is inside the patient and is used to treat or to detect outside to create the diagnostic 
images. 
 Source: https://www.llnl.gov/str/JulAug03/gifs/Hartmann1.jpg. Retrieved May 10, 2013 
With these techniques it is possible to create images of the inside of the body 
without surgery. Additionally, nuclear medicine techniques allow the creation of images 
of the functionality of organs. For example, in making images of the heart or kidneys, 
when the patients are injected with the radioactive material, images taken at different 
times recreate the dynamics of what is happening inside the body. This technique reveals 
how the blood is flowing in organs and how the organs are functioning. Figure 9 shows a 
typical sequence of images from thyroid uptake. Because the images of nuclear medicine 
can be blurry, new machines are able to fuse CT scan images with nuclear medicine 
images for a better localization of the radiation. The newest advance in imaging in 
nuclear medicine is the Positron Emission Tomography (PET); it works with the same 
basics of radiation, but it uses very specific types of radionuclides with very short lives 





Figure 9 Sequence of Images of a Thyroid Uptake 
Source: Personal file 
Nuclear medicine is particularly interesting and complex because it is the only 
field in whitch open radioactive sources are used; this increases the risk of an accident 
and the possibility of a contamination, plus creates the need to deal with radioactive 
waste and mobile sources of radiation. Contrary to the machines used in radiology and 
radiotherapy, the radioactive material in nuclear medicine can’t be turned on and off. The 
radioactive materials used in nuclear medicine tend to have very short half-lives, from 
minutes to days, and to emit different types of radiation depending on the purpose of the 
procedure. For diagnostic images, the intention is to have ionizing radiation that can 
travel long distances so it doesn’t get trapped in the body, so they use gamma radiation. 
In case of cancer or other treatment the idea is to trap the radiation in the specific location 
of the body to kill the cells; in these cases the idea is to use radioactive materials that emit 





ideal, so the radioactive material can do the treatment and be detected outside the body at 
the same time.  
Labor Force in Nuclear Medicine 
The labor force in a nuclear medicine department varies depending on the size 
and the complexity of the procedures available. The general setup of a nuclear medicine 
department is based on the nuclear medicine specialized physician and a technician. 
However, a nuclear medicine department with state-of-the-art technology needs a 
radiopharmacist or radiopharmaceutical chemist, and a medical physicist. 
A radiopharmacist or radiopharmaceutical chemist is in charge of the preparation 
of the radiopharmaceuticals, which are the chemical compounds that are linked to the 
radioactive material so the radiation targets a specific part of the body. Although some of 
the radiopharmaceuticals used in nuclear medicine come ready to use, most of them come 
in kits and need to be prepared in the workplace. The preparation of these compounds 
needs to be done in a very specialized environment to control for contaminants, both in 
the drugs and from the drugs.  
Because of the complexity of nuclear medicine, it is ideal to have a medical 
physicist as part of the department. A medical physicist would assure the safety of 
procedures and the environment and develop internal dosimetry protocols for the 
treatments, like the medical physicist in radiotherapy. 
The professionals working in nuclear medicine today come from different 
backgrounds and in many cases end up in these jobs by chance and with little training. 
For that reason the IAEA published the Nuclear Medicine Resource Manual, which forms 




Nuclear Medicine Supplies 
Nuclear medicine needs two basic supplies besides the labor force. Nuclear 
medicine needs the equipment usually known as gammacameras to detect the radiation 
and the radioactive material. Gammacameras are long-lasting and only need calibration 
and maintenance and there are different suppliers, unlike to the radioactive material. 
The most common material use in nuclear medicine is Techntium-99m; it is used 
in the majority of diagnostic images. It is the ideal radioisotope because it has a half life 
of 6 hours and emits only gamma rays.  Tecnetium-99m is produced as the disintegration 
of molybdenum 99, which is produced in nuclear reactor facilities. Due to the complexity 
of molybdenum production, only seven reactors supply 90% of the molybdenum used in 
the world. The US’s supply of this material depends almost 100% on a single reactor 
located in Canada; the other reactors are located in Europe and South Africa (OECD 
(NEA), 2010). 
For the PET scans it is necessary to have a cyclotron in the hospital or close by in 
order to produce the radioactive materials. Although the machinery is more expensive for 
these exams, once the cyclotron is established it can provide radioactive material for all 
the hospitals nearby. The innovation of this technology is not only the convenience of the 
in situ production of radioactive material, but that PET allows one to see very small 
clusters of cancer cells before they can be seen using the other more conventional 
diagnostic techniques. The reason why this technique is so potent is that the image comes 
from the molecular activity of the cancer cells instead of their physical characteristics. 
This is the latest advance in NM and it has received a lot of attention, not only because of 
its diagnostic power, but because the radioactive material can be produced on site, and 




2 hours. However, the energies of these isotopes are very high and they need to be 
handled with a lot of caution. Table 1 shows the most common used radioisotopes in NM, 
their main use and how are they produced. 
Table 1: Isotopes Commonly Used in Nuclear Medicine 
Isotope Type of Use Production 
I-124/I-123 Diagnostic Cyclotron 
I-131 Diagnostic/ Therapy Nuclear Reactor 
In-111 Diagnostic Nuclear Reactor 
Lu-177 Therapy Nuclear Reactor 
P-32 Diagnostic/Therapy Nuclear Reactor 
Re-186/Re-188 Therapy Cyclotron/Nuclear Reactor(Daugther of W-188)  
Sm-153 Therapy Nuclear Reactor 
Sr-89 Therapy Nuclear Reactor 
Tc-99m Diagnostic Nuclear Reactor (Daughter of Mo 99) 
Y-90 Therapy Nuclear Reactor 
F-18 Diagnostic Cyclotron 
 
 In conclusion, NM is not a new field, but thanks to advances in technology and 
innovation it has evolved to a point where it is possible to take molecular images of the 
human body and to treat illnesses in a targeted way with radionuclide therapies. Despite 
the great possibilities of NM, it is a more complicated field than other medical fields, 
even other fields that also use radiation. The manipulation of open sources of radiation 
and the production of these radioactive materials make this field a very unique one. 
Social and Policy Studies of Nuclear Medicine 
There are many journals that focus on social or policy studies of medicine and/or 
science and technology. However, there are very few papers and documents that focus 
specifically on the field of nuclear medicine. The most significant document on policy 
and nuclear medicine in the US is “Advancing Nuclear Medicine Through Innovation” by 




request from the Department of Energy (DOE) and the National Institutes of Health 
(NIH) to analyze the field of nuclear medicine and to provide areas of significant future 
research for the DOE’s Medical Applications and Sciences Program (MEDICINE, 2007 
p3)a. This is the most comprehensive and formal document that addresses the different 
challenges that NM faces.  
One of the main findings of this NAS publication is the lack of professional 
scientists dedicated to NM in the US (chapter 8). Part of this conclusion came from a 
survey by The Center For Health Workforce Studies (http://chws.albany.edu/). The 
survey was done in 2006, and found that up to that time “[a]s few as 1,500 practitioners, 
nuclear medicine scientists constitute a very small segment of the health workforce in the 
United States—and a tiny component of the entire labor force. Their small numbers are 
not indicative of their importance to both the health care system and the larger economy.” 
(Wing, Langelier, & De, 2007). 
 With respect to what constitutes the workforce of nuclear medicine or what is a 
professional scientist dedicated to nuclear medicine, the IAEA published in 2006 the 
“Resources for Nuclear Medicine.” With this document the IAEA provides guidance to 
what an ideal NM service should have in terms of human resources, technology and 
facilities. In the second chapter of this document they profile the education and training 
that the different roles in the NM workforce should have. Probably the most important 
role in the nuclear medicine department is the one of the nuclear physician, who 
depending on the location could have very different training and responsibilities. There 
are different publications that discuss how NM is taught in different regions and how the 




Scheffler, 2003; Pascual, Dondi, Paez, Kashyap, & Nunez-Miller, 2013; Silberstein, 
2000; Sternberg, 1964). These and other publications on this topic are discussed in 
chapter 4 as part of the education policy data. In the US there are different paths to 
become a Nuclear Medicine specialist, there is a professional position for nuclear 
radiologists (who can only do NM diagnostic images, not therapies), and there are two 
different boards that can certify nuclear physicians (Ziessman, 2012). In Europe this 
distinction in nuclear medicine does not apply. 
 From the professional practice topic there are some interesting papers that discuss 
the role of the radiologist and nuclear medicine physician in the medical field. Diagnostic 
images are usually read or interpreted by a radiologist or a nuclear physician, but a 
diagnostic image is usually done at the request of a different specialist (for example a 
cardiologist, endocrinologist or orthopedist). This participation from different specialties 
to diagnose has opened the debate about the boundaries of radiology: should radiologists 
read images that are going to influence other specialties or should the specialist (not 
radiologist) read the diagnostic of their own specialty? (Burri, 2008). Of course, 
radiologists have a very specific training that allows them to interpret images and 
produce diagnostics of high quality; at the same time their work requires a high level of 
communication with physicians in other specialties. (Sorrell & Reeves, 1997; Sunshine, 
Bansal, & Evens, 1993).  
There are two main technical reasons why radiology and nuclear medicine 
imaging are still their own field. One is that they use radiation for many of the images 
they produce; for this reason they need very specific technology that produces radiation 




possible to know all the radiology and all the other specialty (Sorrell & Reeves, 1997). In 
the case specific to nuclear medicine there was a debate on who should deliver the I-131 
therapy for thyroid: the endocrinologist or the nuclear physician (Baskin, 1997). In this 
case “deliver the therapy” means give the patient a capsule full of I-131, which can be 
done by any of the specialists. More important is all the manipulation of the radioactive 
material and the radioactive patients, which varies greatly around the world (Al-
Shakhrah, 2008). 
 Stefanoyiannis et al analyzed the differences in education for medical physics in 
the field of NM, comparing a number of certifications and educational programs in 25 
European, 2 North American and 2 Australasian countries. They conclude that “a 
common policy on matters concerning education and training as well as the practice of 
the medical physicist profession is generally followed, despite the presence of a few 
differences” (Stefanoyiannis et al., 2012). 
  In the nuclear medicine field it is easier to find comments about policy and 
implementation in the “experts’ opinion” section, the editorial, or the “news” section of 
the nuclear medicine related journals than in policy journals. These comments have been 
present for long time and in a constant manner. They are usually focusing on what is the 
future of the field (Atcher, 2008; Ell, 1993; Farquhar, Stryer, & Slutsky, 2002; A. J. B. 
McEwan, 2002; A. J. McEwan, 2008; Pappas, 2008), calling for policy participation 
(Cannon, 2007), or giving important news for the field, such as problems with the 
radioactive supply (Knight, 2009; Webster, 2009) or the creation of an international 




in the conclusion of technology or science research papers related to the field such as the 
ones made by Graham and Menda (M. M. Graham & Menda, 2011), who state that  
“Current research funding, particularly from the National Institutes of 
Health, overemphasizes the importance of novelty in research projects. 
This emphasis has the effect, in the radiopeptide area, of fostering the 
development of numerous new agents but does not provide the 
infrastructure for the translational effort to bring the agents to 
approval. The regulatory requirements in the United States also restrict 
access to several radionuclides peptides that are being used as clinical 
tools in a growing number of institutions across Europe.”  
The challenges that radiopharmaceuticals face as a result of the regulatory 
approach used in the US is also mentioned in the “Advancing Nuclear Medicine through 
Innovation” document of 2007. The second finding they mention is precisely that 
“There are three primary impediments to the 
efficient entry of promising new radiopharmaceutical 
tracer compounds into clinical feasibility studies: (1) 
complex U.S. Food and Drug Administration (FDA) 
toxicologic and other regulatory requirements (i.e., lack of 
regulatory pathways specifically for both diagnostic and 
therapeutic radiopharmaceuticals that take into account 
the unique properties of these agents); (2) lack of specific 
guidelines from the FDA for good manufacturing practice 
for PET radiodiagnostics and other radiopharmaceuticals; 
and (3) lack of a consensus for standardized image 
acquisition in nuclear medicine imaging procedures and 
harmonization of protocols appropriate for multi-
institutional clinical trials” 
 
One important observation from the commentaries on the US journals is the 
“problems” in communications among practitioners in the nuclear medicine field. There 
are some examples in which the different practitioners seem to be lack of information 
about clinical trials and other processes going on in their areas of expertise. This is 
important because this would affect the implementation of a new technique, although I 




Although various radiopharmaceuticals were labeled as “Orphan Drugs” (drugs 
develop for rare medical conditions) in the 1990’s (Swanson, 1996), including some that 
can be used for cancer therapies, there are very few papers that mention or make 
reference to this fact (just five from a search of "Orphan Drug" And "Nuclear Medicine" 
in PubMed, and one when using “Radiopharmaceutical” instead of “Nuclear Medicine”, 
but there are 1084 results for “Orphan Drug” alone). This is interesting since there are 
many incentives, programs and regulation specific paths for orphan drugs’ research and 
approval; however, this doesn’t seem to be an important factor in the literature review. 
It is possible to find references and complaints about the difficulties that NM has 
faced with the FDA (Callahan, 1996; Komoda, Suzuki, Yanagisawa, & Inoue, 2009; 
Pacific, 1998; Rotman, Laven, & Levine, 1996). The paper by Decristoforo and Schwarz, 
published in 2011 titled “Radiopharmacy: regulation and legislations in relation to human 
applications” is one of the few that developed this topic. Their main focus in is 
radiopharmaceuticals for PET, but the some of the regulations may be shared with the 
radiopharmaceuticals for therapy. This paper compares the differences in frameworks 
between the US and Europe specifically for PET radiopharmaceuticals, finding that in 
both regions the regulatory framework is increasing and that the  
“[r]egulatory authorities need to be aware of the unique 
characteristics of PET RPs [Radiopharmaceuticals], 
including the short half-life and need for single-dose 
patient preparations, to allow incorporation of rapid 
scientific advances in the field. Activities of professional 
organizations may assist in finding appropriate solutions 
for this highly specialized field, but it remains with the 
regulators to support these efforts to allow the true 
potential of PET to develop for use in molecular imaging 
and drug development which will benefit the community at 





There are few papers that analyze the state of the field in different aspects and/or 
regions. They usually compare the statistics of the field by counting the number of 
nuclear medicine departments or services in a region and the type of technologies used, 
mainly based on the implementation of diagnostic tools like PET (not treatment 
therapies) (Dondi et al., 2011; Lass, 2005). One paper focused on nuclear medicine 
technology and policy, but is published in German (Lerch & Jigalin, 2005). In the 
conclusions they show that medical technology is limited in this nuclear medicine 
journal; as a reason they mention the divergence of the development in medical 
technology and in the industry locations as well as discrepancies between the policies and 
the promotion of nuclear medicine techniques in Germany. The IAEA created a Nuclear 
Medicine Database (NUMDAB) to collect information on nuclear medicine practice 
around the world (IAEA-NUMBAD, 2009), but the project is based on self report and by 
May 2013 there were only 2 NM centers reported in USA, and none in France, Germany, 
and Belgium (http://nucmedicine.iaea.org/). 
Radioactive Material for Medical Use 
The third finding of the “Advancing Nuclear Medicine Through Innovation” is 
that there is an inadequate domestic supply of medical radionuclides in the US. They 
suggested that “[t]here is no domestic source for most of the medical radionuclides used 
in day-to-day nuclear medicine practice. Furthermore, the lack of a dedicated domestic 
accelerator and reactor facilities for year-round uninterrupted production of medical 





This is not the first document that the National Academy of Science has published 
about this topic. In 1995 they published “Isotopes for Medicine and the Life Sciences” 
(Adelstein & Manning, 1995), and in 1996 “Radiation in Medicine: A Need for 
Regulatory Reform”(Gottfried & Penn, 1996), both focused on the big applications and 
benefits that the applications of radioactive isotopes have in the life sciences, and the 
barriers it faced. 
More recently in 2012, the National Academy of Science published a book called 
“Assuring a future U.S.-Based Nuclear and Radiochemistry Expertise” where they 
reiterate, “… isotope availability is an important factor for the field. The lack of an 
adequate national supply of medical radioisotopes, especially 99 Mo, creates a reliance 
on foreign sources. Fluctuation in foreign supply streams creates an uncertain future for 
99m Tc radiopharmaceuticals. Development of a national facility for long-lived isotope 
production would reduce the foreign dependence and create more demand for 
radiochemists.” 
From other publications the Journal of Nuclear Medicine published a three part 
special about the future of nuclear medicine, where the first part focused on 
radioisotopes’ availability (“Research Radionuclide Availability in North America,” 
1997), and some other publications called attention to this problem, emphasizing the fact 
that  99m-Tc supply in the US comes from a single reactor in Canada, and every time this 
reactor has had a problem the complete field of NM in the US has to stop (Einstein, 2009; 
Ruth, 2009). 
Europe counts more reactors and facilities that produce radioactive isotopes, and 




are more university and experimental reactors running in general in the EU. The 
European Association of Nuclear Medicine published in 2008 “The medical use of 
radiopharmaceuticals up to 2025” where they show an expected increase in the use of 
some radio pharmaceutics, and an increase in other nuclear medicine techniques. (Group, 
2008). 
Part of the problem in the production of radioactive isotopes comes from nuclear 
reactor waste. It is for that reason that many researchers have tried to develop new forms 
of production, one is the construction of Low Enriched Uranium Reactors (LEU) 
(Fallout, Canada, & Shutdown, 2008; OECD (NEA), 2010; Technology, 2008; Williams 
& Ruff, 2008). Canada has also incentivized the research for options to produce 
radioactive materials, especially for the production of technetium because they know they 
supply a big part of the market with a single reactor, which is old enough to be retired. As 
part of the Canadian efforts some projects have been focused on the production of Tc-
99m in Cyclotrons, one of them resulting in a PhD thesis (Gagnon, 2012). 
Technologies: Effectiveness and Cost-Benefit Analysis 
There are several reviews of new techniques and technologies in NM, and its 
advantages. To begin with, there are a few studies focused on the differences in 
implementation of new technologies. From these studies it is easy to identify that there 
are many differences on the level of adoption of a technology not only at the international 
level but at the national level too. In the paper prepared by the Health Science Center at 
Toronto University, it’s shown how the same technology for breast cancer management, 
the sentinel lymph node biopsy for breast cancer, was adopted unevenly through the 




during surgery and in most standard procedures involves the presence of a nuclear 
medicine physician. With this in mind it was concluded that the factors that had the 
biggest influence in the adoption were the communication with other professionals that 
are part of the treatment, the number of cases in which they can apply these techniques, 
and the administration’s support for the implementation (Wright, Gagliardi, Fraser, & 
Quan, 2011). To draw those conclusions, different type of professionals that were using 
or were accessible to use the technology were interviewed.  
From a technical point of view, there are few studies in the implementation of 
nuclear medicine technologies, mainly at the national level. The Canadian study on breast 
cancer (Wright et al., 2011) mentioned before, and the US study on PET/ CT technology 
(Coleman et al., 2005) have in common the important role that inter professional 
collaboration and the professional guideline development plays in the development of a 
field.  
 There are also several technical reviews that show the effectiveness and 
challenges of some of the latest developments in nuclear medicine therapies for cancer 
also known as radionuclide therapies. This is a topic that has promised results since the 
beginning of the century, evolving from the perspectives of the technology in the field 
(Breeman et al., 2001; de Jong, Kwekkeboom, Valkema, & Krenning, 2003) to more 
technical details of the same techniques (Ambrosini, Fani, Fanti, Forrer, & Maecke, 
2011; Cremonesi, Ferrari, Bodei, Tosi, & Paganelli, 2006).  
The publications by the International Atomic Energy Agency (IAEA) are 
important for this field since it is the organization that coordinates the world effort for the 




right use of radiation. IAEA has a division for human health and a program of action for 
cancer therapy (PACT), both related to nuclear medicine. As part of their work they have 
carried out different research projects to assess the efficacy and validity of nuclear 
medicine compounds for therapy (IAEA, 2007), guides for the research and 
implementation of new radiopharmaceuticals (IAEA, 2009), and the creation of a world 
database to asses the status of the field in the world (IAEA-NUMBAD, 2009), among 
other publications concerned with the quality control, safety and efficacy of more 
traditional nuclear medicine procedures. IAEA also supports research on different 
technical aspects of the technologies that would make a certain technique or innovation 
available for implementation in developing countries, like the in-house preparation of 
radiopharmaceuticals used for treatment and diagnosis in nuclear medicine (Padhy & 
Dondi, 2008).   
There are some groups that have made studies of the implementation of 
techniques in medicine at the international level, none of them related with nuclear 
medicine. The group of medicine of Tokyo University has compared the guidelines for 
hepatocellular carcinoma around the world and with their results they were able to 
conclude that the differences in the guides can be attributed to “various etiological 
factors, high-risk patients, health systems, health resources, medical technology, 
treatment choices and income levels in different countries,” and that the level of 
implementation in each region depends on what entity is writing the guidelines (Song, 
2012). The other common type of articles that compare international implementation of 
health technologies focus mainly on differences between developed and developing 




policies, intellectual property rights when licensing to international companies, and 
international collaborations for the health technology transfer (Salicrup & Fedorková, 
2006). 
Risk Perception and Radiation 
When talking about risk perception and radiation, there are many publications and 
books that address this topic. However, they focus mainly on topics such as nuclear 
power plants, nuclear waste or nuclear weapons. Slovic did one of the most important 
works reviewing the literature on the risk perception of radiation. Among his findings is 
the fact that the perception of risk from radiation varies depending on the sources of 
radiation; for example, medical sources of radiation are perceived as less risky than other 
sources. He points out that none of the papers he reviewed includes nuclear medicine in 
the list of radiation applications in medicine. He also states that “[i]n 20 years of research 
on perception and acceptance of technological risks, there has been remarkably little 
attention given to the medical use of radiation-quite a contrast to the hundreds or more 
studies of nuclear power and nuclear waste” (Slovic, 1996). 
Although many things have changed since Slovic published his paper in 1996, 
there are still very few publications that look at the relation of risk perception and NM. 
However, the NCRP Report No. 160, Ionizing Radiation Exposure of the Population of 
the United States, published in 2009, established that Americans are unnecessarily 
overexposed to medical radiation. That may explain why many of the publications that 
talk about nuclear medicine and risk perception are focused on the design and content of 




and the fact that some doctors don’t know about this risks and order more diagnostic 
images than what is necessary (Freudenberg, Müller, & Bockisch, 2009; Picano, 2000) 
There are no publications that compare the difference in approaches to NM 
between the EU and the US. However, the EU commission clearly states, “The 
precautionary principle … aims at ensuring a higher level of environmental protection 
through preventative decision-taking in the case of risk. However, in practice, the scope 
of this principle is far wider and also covers consumer policy, European legislation 
concerning food and human, animal and plant health” (European Comission, 2000). 
In conclusion, the research in nuclear medicine is well documented; thanks to 
IAEA there are some worldwide standards in nuclear medicine. However, there are 
differences in the time of implementation of some techniques, mostly in radionuclide 
therapy that need to be explored since they can potentially affect patients in the regions 
where its implementation is slow. It is important to keep in mind the differences on risk 
perception that this topic brings to the table since radiation and its medical applications is 
more acceptable, but in order to do NM it is necessary to run nuclear plants that are seen 





CHAPTER 3 – METHODS AND DATA 
 
Nuclear medicine is different from all other medical fields. Chapter two explains 
in detail what are the physics principles behind the NM images and treatments. The 
second part of chapter two shows the wide spectrum of publications that relate NM and 
policy. However, the questions that motivate this project are not answered there. This 
chapter gives a detailed explanation of the data that I collected to answer the question, 
how and why the documents were selected, and how they were analyzed. 
Data  
The data was collected from websites from professional organizations and 
regulatory agencies. It consists of documents, publications, and laws publicly available. 
The dependent variable consists of the practice guidelines and case reports that allow 
investigating the hypothesis that Europe implements radionuclide therapies before and at 
higher levels than the US. The independent variable consists of the policies that may 
affect NM, and its relationship with the technology. 
Dependent Variable 
The dependent variable is the time and quantity of implementation of radionuclide 
therapy technologies. In order to answer the first question (Are radionuclide therapies 
implemented more in EU than US?) I assumed that the practice guidelines from the 
professional societies as well as the case reports account for the day-to-day practice in 
NM.  
The Practice Guidelines 
The definition of clinical practice guidelines has changed with time, but the most 




patient care that are informed by a systematic review of evidence and an assessment of 
the benefits and harms of alternative care options” (R. Graham, Mancher, & Wolman, 
2011). This definition is commonly accepted, and supports the assumption of a practice 
guideline as evidence of implementation. The use of practice guidelines had increased 
since the 1980s for different reasons, and one of the main reasons for this is the need for 
standardizations in the medical field (Pickett, Waterstram-Rich, & Turner, 2000). The 
efforts for standardization are evident in the EU publication of “Recommendation of the 
Council of Europe on Guidelines Methodology” (MINISTERS EUROPE COUNCIL OF 
COMMITTEE, 2001), the US National Guideline Clearinghouse 
(http://www.guideline.gov), and the different international efforts such as the Appraisal 
of Guidelines for Research and Evaluation (AGREE) Instrument 
(http://www.agreetrust.org/), and the Guidelines International Network (http://www.g-i-
n.net/). Therefore, in order to check for the differences in the NM field between the EU 
and the US I analyzed the practice guidelines available on the websites of the (American) 
Society of Nuclear Medicine and Molecular Imaging (SNMMI), whish are published in 
the practice section of its website (http://interactive.snm.org/index.cfm?PageID=772), 
and the European Association of Nuclear Medicine (EANM), which are published in the 
publications section of its website 
(http://www.eanm.org/publications/guidelines/index.php?navId=37). The last day in 
which these sites were checked was July 1, 2013. The details of the analysis are later in 
the chapter. 
In order to use the practice guidelines published on the websites of the 




at different levels to analyze the implementation of radionuclide therapy techniques in the 
EU and the US, each document was downloaded from the website and then classified 
based on different criteria. For the analysis I only use unique guidelines that were 
approved by the respective society and published on the website.  
The SNM has publisheded 53 procedures, divided in 14 categories while EANM 
has 61 in 17 categories. The categories are listed in Table 2, and although they don’t 
match perfectly they can be compared (for a complete list of the Practice guidelines refer 
to Appendix A). Some guidelines files listed by SMN are duplicated on its website. For 
example the guide on “Pediatric dose consensus guidelines.” Additionally, SMN has 9 
guidelines in collaboration with the American College of Radiology (ACR), and 8 of 
them are also in collaboration with the Society for Pediatric Radiology (SPR). However, 
there are other SNM-only guidelines on the website that describe the same procedures as 
some of the collaboration guidelines. From these 9 collaborative guidelines, two are there 
repeated “ACR–SNM–SPR PRACTICE GUIDELINE FOR THE PERFORMANCE OF 
PARATHYROID SCINTIGRAPHY, 2009” and “SNM Practice Guideline for 
Parathyroid Scintigraphy, 2011.” From these two I selected the SNM-only one to code 
because is the most recent. There are four other guidelines from the collaborative group 
that are very similar to the other SNM-only guidelines, for example “SNM Practice 
Guideline for Lung Scintigraphy, 2011” from SNM only and “ACR–SNM–SPR 
PRACTICE GUIDELINE FOR THE PERFORMANCE OF PULMONARY 
SCINTIGRAPHY IN ADULTS AND CHILDREN, 2009.” Because the guidelines were 





Table 2: Number of guidelines in SNM and EANM websites and their classifications 
 
The EANM have one duplicate practice guideline, the “Guidelines for standard 
and diuretic renogram in children” which is posted twice, with two different files, one 
2011 and the other one 2000. In this case I kept only the most recent file for coding 
because the aim is to have only unique documents. EANM has multiple guidelines in 
collaboration with other European societies, but the practice guidelines are not duplicated 
on their website. 
Besides guidelines, the EANM has listed three papers that are not practice 
guidelines. Two of them, “Curriculum for education and training of Medical Physicists in 
SNM Number of 
documents 
EANM Number of 
documents 
Cardiac 2 Cardiology 3 
Endocrine 4 Parathyroid 1 
Infection 3 Inflammation/Infection 2 
Neurology 4 Neuroimaging 5 
Oncology 8 Oncology 13 
Musculoskeletal 2 Radionuclide Therapy 9 
  Dosimetry 3 
Pediatric 5 Paediatrics 10 
Pulmonary 1 Pulmonary Embolism 2 
Gastrointestinal 3   
General 5 Radiopharmacy 2 
  Drug Development 1 
  Physics 2 
  Technologist Guidelines 5 
Collaborative 
Guidelines 10   
  EANM:SNMMI Guidelines 1 
Retired 
Guidelines 3   
EANM 
Guidelines 3 
SNMMI Guidelines - 
endorsement by EANM 2 




Nuclear Medicine” and “Integration of FDG-PET/CT into external beam radiation 
therapy planning” are kept for the coding because they clearly state that EANM has 
endorse them and/or are product of a EANM work. The third file is “PET in radiotherapy 
planning: Particularly exquisite test or pending and experimental tool?” which is a 
compilation of reviews of the topic, but do not present statements from the EANM. For 
this reason it is not used in the Nvivo coding. EANM also listed the Power Point 
presentation of the “Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT” 
guideline, which is not used for the coding. 
There is one guideline that was developed in collaboration between EANM and 
SNM and is the “SNM/EANM Guideline for Guideline Development 6.0” in 2012. As its 
name indicates, this guideline set the methodology for the creation and approval of 
guidelines in the field of nuclear medicine; it also states that for non-collaborative 
guidelines the approval doesn’t need to come from both societies. The goal of this 
guideline is to have multiple collaborations and endorse guidelines in the future. Because 
this guideline was developed in collaboration, it was counted as a document for both 
societies in the Nvivo coding. 
There is a guideline in EANM website listed as a joint guideline developed with 
SNM and IAEA, but it is not published yet in the SNM website. The name of the 
guideline is “The joint IAEA, EANM, and SNMMI practical guidance on peptide 
receptor radionuclide therapy (PRRNT) in neuroendocrine tumors (2013).”  Because the 
guideline is not listed in the SNM website and it was published in the European Journal 




One of the most important limitations of the data is the existence of the already 
mentioned joint guidelines, and the guidelines endorsed between the regions. For the joint 
guidelines, there is no doubt about them belonging to both regions’ data sets; however, I 
took a different approach with the endorsed guidelines. The reason to do this is the lack 
of clarity about the European guidelines validation by the FDA in the US. Not all the 
physicians can practice them, which indicates low implementation. There are three 
guidelines from EANM endorsed by SNM and two from SNM endorsed by EANM; these 
guidelines are listed in Table 3. These guidelines were only coded to their original 
societies for the Nvivo coding. 
Table 3: Endorsed Guidelines 
Guidelines from EANM endorsed by SNM Guidelines by SNM endorsed by EANM 
131I-meta-iodobenzylguanidine (131I-mIBG) 
therapy (2008) 
Breast scintigraphy with breast specific 
gamma cameras 1.0 (2010) 
131I/123I- Metaiodobenzylguanidine (MIBG) 
scintigraphy (2010) 
Sodium 18F-fluoride with PET/CT bone 
scans (2010) 
Radioimmunotherapy for B-cell lymphoma with 




 EANM has a section for technician “guidelines,” but these are more like 
pamphlets of information and are not assigned to a particular procedure; for this reason 
they were not taken into account for the Nvivo coding. 
 Finally, both societies have “retired” or outdated guidelines published on the 
website. The EAMN disclaimer says: “Authoritative source: Dr. Richard Wolf, LL.M. 
Partner (legal advisor) Please note that this guideline has not been updated since 2003 
and, therefore, may not reflect the current knowledge and practice in the field of 
oncology. EANM is providing this guideline on an ‘as is’ basis for general information 




currency, relevance, reliability or suitability of the information contained therein.” The 
SNM disclaimer says “Please note the below guidelines have been retired and thus not 
updated since their last approval. Therefore, these guidelines may not reflect current 
knowledge and practice in the field of nuclear medicine. SNMMI is providing these 
guidelines on an 'as is' basis for general information purposes only and does not accept 
any responsibility for accuracy, completeness, currency, relevance, reliability or 
suitability of the information contained therein.” In both cases the guidelines were used in 
the Nvivo analysis. From the total of 115 documents, only 12 were not part of the 
analysis in Nvivo. The findings and analysis of the data are presented in chapter 4. 
Bibliometric Analysis of Case Reports 
In addition to the practice guidelines a bibliometric analysis was conducted with 
publications that contain the keywords (“radionuclide therapy” AND case AND report) 
OR (radioinmunotherapy AND case AND report) in PubMed, Medline, Biosis Preview, 
and ISI Web of Knwledge databases. This query was intended to find case reports that 
contained the words “radionuclide therapy” or “radioinmunotherapy.” The term 
“radioinmunotherapy” refers to a specific type of radionuclide therapy in which the 
radioactive material is linked with antibodies, and is mainly used for non-Hodgkins 
lymphoma. 
Based on the definition of case reports, these are also assumed to be evidence of 
implementation of a technique since they are detailed reports of the practice, and would 
not exist if the technique were not being used. There were 61 publications from PubMed, 
16 from Medline, 23 from Biosis Preview and 46 from ISI Web of Knowledge. After 




I assume that the practice guidelines are published because the technologies and 
techniques in those guidelines are widely used in the regions, and that all the practitioners 
have incentives to work with them and to publish case reports. Nevertheless, it is possible 
that the practice guidelines don’t represent a spectrum of the techniques that are used in 
the day to day practice because it take time to publish them or because some techniques 
may not be in the interest of those who published the guidelines. Additionally, 
practitioners may not have interest in publishing their case reports or may be 
disseminating their knowledge and evidence of implementation in a different form, such 
as conferences. A more direct way to measure the implementation of a technique is by 
surveys and interviews of medical centers, medical staff, and records of procedures, but it 
is not possible to use them for this specific project due to funding and time. Therefore, 
this project and the variables measured here were selected because the data sources are 
publicly available and provide a view of what is officially happening in terms of the 
technologies implemented and supported by the professional societies in the field. 
Independent Variable 
The independent variable of this study is the policies of the two regions. The risk 
of using radiation and the consequences of its uncontrolled use caused the creation of 
many of the regulatory frameworks that we use today. All of them are based in the “as 
low as reasonable achievable” (ALARA) principle, which means that ionizing radiation 
doses should be as low as possible for the public and workers while using the properties 
of radiation for the desired application. Specific practices, and especially accidents with 
radiation, have motivated most of the regulatory and policy changes related with 




traditionally very regulated and accidents in these fields have not created any recent focal 
events that could promote specific policies.  It is possible that the use of new techniques 
and technologies promotes the creation of new regulation and policies in nuclear 
medicine. A good example of this is the situation of PET and the development of new 
radiopharmaceuticals for diagnostic use that can be manufactured in the hospital. 
Nevertheless, the case of radionuclide therapies is different because the materials come 
from very traditional regulated sources, and variations of the technique have been used 
for more than 50 years. The possibility of nuclear medicine techniques influencing the 
policy changes in the policies related to nuclear medicine, as well as the different levels 
of regulation, make it difficult to elaborate a solid causal relation, but it allows one to 
place the implementation of radionuclide therapy techniques in a policy context that may 
elucidate the state of the implementation. This section presents the different types of 
policies and regulations that surround NM. The types of regulations explored are related 
to radiation regulations, health regulations, and education regulations, in international, 
European Union and United States arenas. 
The Policies Involved in Nuclear Medicine 
In order to account for the differences in when particular treatments were 
introduced in the field, I checked the policies from the two regions that affect the nuclear 
medicine field. Because of the nature of the field, there are more regulatory bodies that 
affect the practice of NM than other medical fields. Besides the normal health policies 
and drugs I researched the procedures for implementing new radiopharmaceuticals and 
the classification of radiopharmaceutical drugs in the different regions, because these 




The policies and regulations related to radiation and radiation protection shows 
how precautionary the different regions are with respect to the uses of radioactive 
materials. If the policies are strict and/ or complicated I expect to find that the region 
implements the technology more slowly than others. There is also the fact that different 
agencies can be in charge of the same topics; for example, environmental agencies and 
energy agencies can regulate about radiation protection matters that can overlap, and may 
or may not coincide in the same region, creating an overregulation on the same topic, 
which add to the issues for the nuclear medicine practitioners in order to move on. 
Regulation of the production of radioisotopes is also a very important part of the 
regulatory policies that doesn’t apply to other medical fields. In this case the regulatory 
bodies are lokely to be the same as the ones regulating nuclear power plants, because 
many of the radionuclides used in NM are produced in these types of facilities. The other 
option for radioactive material production is the cyclotron, which is mainly used in PET 
imaging. As mentioned before, there are very few plants that produce this type of 
material, and they are mainly managed by the local governments, which assume the risks 
and costs of the power plants. The existence or not of regulation for the production of 
radioactive material for medical use, and the characteristics of the regulations is very 
important for the development of the NM field in the two regions, because without 
constant and secure availability of radioisotopes there is no certainty for the future of the 
field. The supply-demand problem has been one of the most emblematic of the NM field 
after the shortage of material that NM facilities have gone through in the recent past. 
Additionally, I investigated the differences in the education programs for medical 




in the different regions, because the regulations on the NM specialist profession would 
account for differences in the field between different regions. The efforts to standardize 
practices are not only limited by the differences in practice guidelines, but by the 
qualifications that different professionals need in order to work. Different educational 
paths may bring professionals to the same certifications, but that doesn’t guarantee their 
knowledge to be similar. The strength professional qualifications would also reflect the 
level of knowledge transfer that is needed to practice. For example, a regulation that 
makes professionals renew their credentials through specific examinations is more likely 
to keep professionals in the field up to date on techniques and knowledge than a lack of 
regulation or credentials. 
Radiation Regulation 
International 
Radiation regulation is a very complex topic that is usually divided among nuclear 
energy, peaceful applications of radiation, and nuclear weapons. Most of the regulations 
regarding radiation fall under these three topics. The projects and applications that are 
radiation related have a lot of intervention from the government and from international 
organizations, due to the risk and cost involved in these topics. There are two important 
international organizations that focus their studies on safe limits of radiation dosis, and 
set the standards that shape national and local regulations around the world are the 
International Commission on Radiological Protection (ICRP) and the International 
Commission on Radiation Units and Measurements (ICRU). Based on the 




amount of radiation that the public, the health practitioners, and children should receive 
under different situations. 
The International Atomic Energy Agency (IAEA) is one of the most active and 
important agencies regulating radiation in the world. In order to assure that the use of 
radioactive material is limited to pacific and safe uses, the IAEA conducts inspections in 
countries with nuclear reactors and important nuclear facilities. Additionally, the IAEA 
has a special division for human health applications of radiation. In this division they 
realize different projects related to nuclear medicine that result in publications that are 
publicly available through their website (http://www-
naweb.iaea.org/nahu/NM/publication.html). By March 2013 they had nine technical 
documents, eleven human health series, one human health report, two training courses, 
five safety report series, and nine technical report series in NM topics (a list of these 
documents is provided in Appendix B). These documents create standards and serve as a 
reference for NM practice around the world. Their documents go from planning a NM 
center to how to label radiopharmaceuticals.  One of the most influential documents of 
IAEA is the general manual for NM, where they propose a syllabus for all the professions 
related to NM (IAEA, 2006). 
Additionally, the IAEA has tried to develop a database of all the nuclear medicine 
centers in the world and their practices (http://nucmedicine.iaea.org/default.asp), but U.S 
centers are not actively participating (by July 7, 2013 only 3 had reported anything), and 
not all the EU countries are reporting. Furthermore, the IAEA has databases of 
radioisotopes for medical production (http://www-nds.iaea.org/medical/) and reactors that 




this information, there are 15 operational reactors capable of isotope production in the US 
(listed in Table 3), and 13 in Europe (listed in Table 4). 
Table 4: List of Nuclear Reactors in US Capable of Isotope Production 
Source: retrieved from http://nucleus.iaea.org/RRDB/Content/Util/IsoTopes.aspx July 1 2013 
FACILITY NAME TYPE LAST UPDATE 
AFRRI TRIGA TRIGA MARK F 26/05/2011  
ATR TANK 09/04/2013  
MITR-II MASS. INST. TECH. TANK 09/05/2011  
HFIR TANK 22/03/2012  
OSTR, OREGON STATE UNIV. TRIGA MARK II 09/04/2013  
PSBR PENN ST. UNIV. TRIGA MARK CONV 23/12/2010  
RRR REED COLLEGE TRIGA MARK I 09/03/2012  
NSCR TEXAS A&AMP;M UNIV. TRIGA CONV 16/08/2012  
GSTR GEOLOGICAL SURVEY TRIGA MARK I 09/04/2013  
UCI, IRVINE TRIGA MARK I 09/04/2013  
UFTR UNIV. FLORIDA ARGONAUT 09/04/2013  
MURR UNIV. OF MISSOURI TANK IN POOL 13/08/2012  
WSUR WASHINGTON ST. UNIV. TRIGA CONV 09/04/2013  
UC DAVIS/MCCLELLAN N. 
RESEARCH CENTER 
TRIGA MARK II 09/04/2013  
TRIGA II UNIV. TEXAS TRIGA MARK II 09/04/2013  
 
Table 5: List of Nuclear Reactors with Isotope Production Potential in Europe 





BELGIUM BR-2 TANK 14/06/2012  
CZECH 
REPUBLIC 
LVR-15 REZ TANK WWR 09/04/2013  
FINLAND FIR-1 TRIGA MARK II 09/04/2013  
FRANCE OSIRIS POOL 14/01/2013  
FRANCE HFR HEAVY WATER 09/04/2013  
FRANCE ORPHEE POOL 08/07/2012  
GERMANY FRMZ TRIGA MARK II 10/10/2010  
GERMANY FRM II POOL 09/04/2013  
NETHERLANDS HOR POOL 30/05/2010  
NORWAY JEEP II TANK 28/06/2013  
POLAND MARIA POOL 09/04/2013  
PORTUGAL RPI POOL 09/04/2013  
ROMANIA TRIGA II PITESTI 







Besides the IAEA, the Organization for Economic Co-operation and Development 
(OECD) countries have created a Nuclear Energy Agency whose mission is 
"To assist its member countries in maintaining and 
further developing, through international co-operation, the 
scientific, technological and legal bases required for a safe, 
environmentally friendly and economical use of nuclear 
energy for peaceful purposes. To provide authoritative 
assessments and to forge common understandings on key 
issues as input to government decisions on nuclear energy 
policy and to broaden OECD policy analyses in areas such 
as energy and sustainable development. (OECD-NEA, 
2013)” 
One of their work areas is medical radioisotopes; it was established in 2009 with a 
High-Level Group on the Security of Supply of Medical Radioisotopes (HLG-MR). Their 
main concern is the dependability of supply of Tc-99m in their countries and the world. 
As a result they have five publications on the supply of medical radioisotopes, but they 
are focused on Tc-99m and I-131. They found that the pricing structures of radionuclides 
do not reflect the cost of the production. Additionally, the lack of coordination between 
different reactors causes the extra cost of overproduction. These two findings add to the 
fact that there is not a transparent system to understand the cost and price dynamic of the 
production of radionuclides, and the role of governments in this chain is not always clear. 
Moreover, there is not consistency on the policy approach to this issue from the different 
governments that are affected. This group proposed policies for the participant countries 
that implicate market reforms such as full cost recovery of production, a shift in 
government participation, and subsidies for isotope production activities. They also 
suggest incentives for R&D related to alternative technologies for isotope production 




To summarize, ICRP and ICRU are the international intuitions that set standards 
for maximum levels of exposure to radiation, among other scientific measures. 
Additionally, the IAEA and NEA from OECD are the two most influential organizations 
that influence the policies of radiation practices internationally. The work of these 
organizations is in many cases complementary, and they work together on many projects. 
Now I am going to explore the organizations that influence NM policies at the regional 
level in the EU and the US. 
European Union 
The European Union has its own agreements in the radiation field. The European 
Commission, which is the executive body of the European Union, has legislated on 
nuclear energy topics almost since the creation of the EU. The “Treaty Establishing the 
European Atomic Energy Community” (Euratom) was signed for the first time in 1957, 
its principal objectives to promote research and knowledge transfer, to establish safety 
standards for work with radiation, to ensure the basic needs/ supplies for the development 
of nuclear energy, and to control the use of nuclear material and assure that it is used for 
peaceful purposes (EU, 2007). 
The Council Directive 97/43 of Euratom legislates on medical radiation exposures 
and article 6, item 3 says  
“In radiotherapeutic practices, a medical physics expert shall be 
closely involved. In standardized therapeutical nuclear medicine 
practices and in diagnostic nuclear medicine practices, a medical 
physics expert shall be available. For other radiological practices, a 
medical physics expert shall be involved, as appropriate, for 
consultation on optimization including patient dosimetry and quality 
assurance including quality control, and also to give advice on matters 
relating to radiation protection concerning medical exposure, as 




With this statement the Euratom mandates the presence of medical physicists in 
all the nuclear medicine services that provide therapies. Additionally, in the guidelines of 
EANM there is a proposed syllabus for Medical Physicists. With these tools, NM 
services in the EU assure the presence of capable personnel in their facilities. 
Additionally, different countries of the EU have acknowledged the use of the proposed 
syllabus by IAEA for the medical practitioners. This syllabus includes the study of 
radionuclide therapies in the NM specialist education. 
EANM also has a guideline for the application of new drugs, that details the legal 
processes for the acceptance of new drugs, clinical trials, etc. This guideline is especially 
important for young or foreign researchers that are not used to the system.  
United States 
 The Nuclear Regulatory Commission (NRC) was established by the Energy 
Reorganization Act of 1974. This organization manages all the regulations on nuclear 
power plants, radioactive waste, licenses for manipulation of radioactive material, etc. In 
these regulations the medicine applications are in Title 10 of the code of Federal 
Regulation part 35 –Medical use of byproduct material, and part 70-Domestic use of 
special material. 
The NRC shares the regulation of radionuclides used in medicine with the FDA. 
On the main website of the FDA there is a tab for Radiation-Emitting Products; however, 
none of the classifications they have is for nuclear medicine applications (last checked 
July 8, 2013). The path for radiopharmaceutical approval starts with the application for 
an Investigational New Drug Application (IND), follow by a clinical trial or clinical 




complicated than for a diagnostic procedure, and an application for FDA approval need to 
include efficacy (Decristoforo & Schwarz, 2011).  
 The Department of Energy also plays an important role in the nuclear medicine 
fields because the production of medical isotopes in the US is coordinated by the 
“National Isotope Development Center” (NIDC). This center also manages the 
distribution of isotopes in the US. The isotope production site lists nine reactors; the 
locations of the reactors and the isotopes they produce are shown in Figure 10. The 
information on these reactors was updated in 2011, and for this reason may not be the 
same as that on the IAEA website in Table 3. 
 
Figure 10 Isotope production sites 
Source: Retrieve from http://isotopes.gov/sites/sites.html, June 20, 2013 
 
 From the different documents presented previously in this manuscript it is evident 
that these nuclear reactors don’t supply the US market optimally. For that reason, plus the 
initiatives of the OECD-NEA, the bill S. 99 (112th): American Medical Isotopes 
Production Act of 2011, was introduced in January 2011. Sections 3 and 6 of the bill 




“Directs the Secretary of Energy (DOE) to implement a technology-neutral program to 
evaluate and support projects for the production in the United States (except in certain 
circumstances without the use of highly enriched uranium) of significant quantities of 
molybdenum-99 for medical uses, implemented in cooperation with non-federal entities, 
whose costs shall be shared in accordance with certain cost sharing requirements of the 
Energy Policy Act of 2005,” and section 6 “Amends the Atomic Energy Act of 1954 to 
authorize the NRC to issue a license, or grant an amendment to an existing license, for 
use in the United States of highly enriched uranium as a target for medical isotope 
production in a nuclear reactor, but only if specified conditions are met, including 
certification by the Secretary that the federal government is actively supporting 
development of an alternative medical isotope production target that can be used in that 
reactor. (American Medical Isotopes Production Act of 2011 LIBRARY OF CONGRESS 
SUMMARY, 2011)” This bill died after it passed the Senate on November 17, 2011. 
Besides the challenges in supply of NM materials, professionals working in 
nuclear medicine face different challenges from the educational policies. First, the 
physicians have two paths to be certified as nuclear medicine specialists. The Board of 
Radiology has a specialization in nuclear medicine radiology that only includes 
diagnostic images, and the Board of Nuclear Medicine has its own certifications that 
include therapies. There is not a standardized curriculum for these physicians; while 
some take 3 years of radiology and one of nuclear medicine, others may have four years 
in nuclear medicine. The definitions of nuclear radiology and nuclear medicine are not 
clear, and that is why there are some overlapping practice guidelines between the ACR 




education of medical physicists also shows that different states regulate the presence of 
medical physicists in nuclear medicine facilities differently. This is also evident in Figure 
11 from the website of the American Association of Medical Physicist (AAPM), where 
they list the state regulations and licensures for medical physicists in the US. 
Additionally, by 2011 there were only two postgraduate programs on radiopharmacy in 
the US while the EU has many of these programs already established for years 
(Decristoforo & Schwarz, 2011) . 
 
 
Figure 11 Medical Physicist Regulations and Licensures by State 
Source: Retrieve from http://www.aapm.org/government_affairs/licensure/default.asp July 15, 2013 
Methods of Analysis and Limitations 
 
The analysis of the practice guidelines was facilitated by using the text analysis 
software Nvivo, which supports qualitative research by allowing the search of words in 
multiple documents at the same time, coding entire documents or parts of documents for 
different classifications, running the frequency of words in and among documents, and 




In order to find when the techniques were implemented first, the initial objective 
was to identify when the guidelines were first published. The first classification used with 
the practice guidelines was time. Because many of the guidelines have been reviewed 
and/or have different iterations, I also classified them per version. In order to do this I 
searched for older versions in the official journals of the societies. However, I found that 
not all the guidelines were published in the society journals, and in some case the files for 
a guideline are not the same as on journal and in the website, although the content may be 
almost identical. 
The guidelines were also compared by topic, using the classification that the 
websites provide, and then paired one to one to see if they had analogous guidelines in 
the other region.  They were further classified as diagnostic, therapy or general, based on 
the intended purpose of the procedure. Classified as general or miscellaneous were 
guidelines such as the guideline for guideline development, practice of good reports in 
dosimetry, or the ones about preparation of medication and radiopharmacy. This 
classification makes visible distinctions between the different uses of nuclear medicine 
between regions. 
Finally, using the features of Nvivo, I searched for names of different 
radionuclides across the guidelines. For example, the radionuclide Technetium 99m was 
searched as Tc-99m or 99m-Tc or 99m-Technetium, and coded under the same category 
every time it appeared in a guideline. This allowed me to evaluate when the radionuclide 
technologies introduced in the guidelines were published, what radionuclides are used in 




For the bibliometric analysis I used the bibliometric software Vantage Point (VP). 
After downloading the records from the different databases, I merged the records in VP, 
then cleaned the list of titles to assure that the records were not duplicated. Sometimes, 
the same titles had different uses of capital letters or periods, which was easy to fix with a 
“clean list” query already provided by the software. After that, I merged the duplicate 
data so it retained the different information provided from the different databases. Then I 
merged the fields of country and country of affiliation to assure all the records had this 
field. The same procedure was done with the year. These were the only two fields of 
interest since the information I needed was region and date of publication. I cleaned the 
names of countries for different spellings such as The Netherlands and Netherlands. Then 
I proceeded with the analysis and results, which are presented in the following chapter. 
The analysis of the policies is qualitative, and no special software or text analysis 
was done. It focused on the relationships that the policies have with NM and how they 
affect the implementation of radionuclide therapy techniques. This analysis is presented 
in the following chapter after the results of the practice guidelines and bibliometric 
analysis, and leads to the conclusions of the project. 
Because the data for this project is limited to the information publicly available on 
the Internet, and the time frame to develop the project is constrained, the analysis is more 
descriptive than explanatory. It is focused on understanding the state of the art of nuclear 
medicine as a practice and particularly the use or implementation of radionuclide therapy. 
The study has produced observations of differences in the policy context that inform the 




require a larger study. The following chapter undertakes an explanation of how the 






CHAPTER 4 – ANALYSIS AND FINDINGS 
Up to this point, chapter two explains the details of the science and the variety of 
publications that mention NM and policy. This chapter also clarifies why NM is different 
from all other medical fields, and how little has been written about the importance of the 
field and the policies that surround it. Chapter three describes the data used to test the 
hypothesis that Europe implements radionuclide therapy technology before and more 
than the US because of the regions’ different policy environments. The data for the 
dependent variable, time and quantity of implementation, consists of the practice 
guidelines from the different professional societies and the publications of case reports. 
The data for the independent variable consists of policies that affect the nuclear medicine 
field. Chapter three explains in detail how the data was selected and what the plan of 
analysis is. Now I present the results of the analysis, and the findings. 
Results 
Practice Guidelines 
After carefully coding the 103 practice guidelines from EANM and SNM in the 
Nvivo software, and adding additional information such as older versions of the same 
practice guideline, I proceeded to analyze the data. The first inquiry was the time of 
implementation of the different nuclear medicine techniques; in order to do it I checked 
for the date of publication of the different guidelines. Table 5 shows the number of 
guidelines published each year and the version of each guideline. From the table it is easy 
to notice that SNM has guidelines with more iterations than the EANM. All the EANM 
guidelines are first or second versions. Europe has an especially high productivity in 
2009-2010. One of the guidelines with version 6 for SNM is the joint “SNM/EANM 




EANM. The first version was published by SNM in 1996. For this reason it was not 
counted as an old version for the EANM case. The information about older versions was 
obtained mainly through the search of the guidelines in the official journals of the 
associations. 








1 2 1 2 3 4 5 6 
1999 0 0 0 1 1 0 0 0 0 2 
2000 1 0 1 0 0 0 0 0 0 0 
2001 0 0 0 0 0 1 0 0 0 1 
2002 3 0 3 2 0 1 0 0 0 3 
2003 4 0 4 0 0 6 0 0 0 6 
2004 0 0 0 0 1 3 0 0 0 4 
2005 1 0 1 0 0 0 0 0 0 0 
2006 2 0 2 1 0 3 0 0 0 4 
2007 3 1 4 0 0 0 1 0 0 1 
2008 4 2 6 0 0 2 0 0 0 2 
2009 7 4 11 1 0 3 0 4 0 8 
2010 11 1 12 2 0 0 1 3 1 7 
2011 2 1 3 1 1 1 0 1 0 4 
2012 2 0 2 0 1 1 2 0 1 5 
2013 3 0 3 0 0 0 0 0 0 0 
Total 43 9 52 8 4 21 4 8 2 47 
 
Based on the year of publications of the first guidelines (version 1), the US clearly 
moved earlier than the EU in the NM field. Table 7 presents the years in which the 
guidelines with more than one version were published. This table provides evidence that 
the SNM started working in practice guidelines at least 6 years before the EANM. There 
are two cases for each association where the first version of the guideline was not 
available. 1996 and 1997 seem especially productive for SMN. Having in mind that the 
SNM was founded in 1954, and the EANM in 1985, it is understandable the delay in the 




Healthcare and Policy and Research was created in US, and in 1990 the National 
Academy of Science published “Clinical Practice Guidelines: Directions for a New 
Program” (Field & Lohr, 1990). These two events incentivized the creation of practice 
guidelines in the different medical fields, and that may explain the increase in practice 
guideline production in US in the mid-1990s. In conclusion, the US field began 
publishing procedures in nuclear medicine before the EU; however, the EU has more 
practice guidelines today. 
Table 7: Year of first publication of guidelines with more than one version 
Fist Version Europe US 
1994 0 1 
1995 0 4 
1996 0 11 
1997 0 10 
1998 0 5 
1999 0 3 
2000 1 0 
2001 0 1 
2002 2 1 
2003 4 1 
Unknown 2 2 
 
Moving towards the content analysis of guidelines, I compared the classifications 
that each society has for them (Table 1). Although there are many classifications that are 
comparable or the same, such as cardiology from EANM and cardiac from SNM, there 
are some that are very different. For example, there are differences in the way the two 
societies classify oncologic procedures. In the SNM classification they include diagnostic 
and therapeutic procedures, while the EANM divides these procedures in two; the 
oncology classification contains all the diagnostic images, and in the radionuclide therapy 




also has categories the SNM doesn’t have; moreover, SMN doesn’t have any guidelines 
that cover some of those topics; for example, there are not specific guidelines in 
dosimetry in the SMN, while the dosimetry section of EANM has five practice 
guidelines; one of them is a heavy math supplement of one of the other guidelines. 
Although some of the extra classifications from the EANM are guidelines for 
doctors, some others are intended for other professionals in the nuclear medicine field, or 
are for procedures that do not involve direct interaction with the patient, like the physics 
section and the radiopharmacist section.  
In order to check for the differences between the practice guidelines between the 
two regions, I paired them by procedure, taking into account type of procedure, 
anatomical specifications and radioactive material use. There are 10 guidelines in SNM 
that don’t have a pair in EANM, but they are all related to diagnostic procedures. There 
are 28 EANM guidelines that don’t have a pair in SNM. These include guidelines for 
how to introduce a new drug into the EU market, and several guides in dosimetry, but the 
main difference is in guidelines related with oncology and therapy. This provides 
evidence that the EU is working in a wider spectrum of topics than the US.  
Additionally, I coded each guideline in Nvivo as diagnostic, therapy or general 
(miscellaneous information). Table 8 shows the results of this counting. SNM has more 
diagnostic guidelines than EANM, but EANM has five times more practice guidelines in 
therapy. In the general category, there is one joint guideline that is counted for both 
regions, but EANM has more guidelines in this aspect. Although in general, EANM has 
more guidelines, the big difference in guidelines for therapy is interesting, and it gives 




Additionally, SNM has more guidelines in the diagnostic areas, but some of these 
guidelines come from the collaboration with the ACR, and overlap with other SNM-only 
guidelines, so this does not necessarily show more technologies adopted by the SNM in 
the diagnostic part of the practice. 
Table 8: Type of practice guideline procedure by region 
  Europe US 
Diagnostic 32 40 
General-miscellaneous 9 7 
 Therapy 13 2 
 
The two guidelines from SNM endorsed by EANM listed in Table 2 are 
diagnostic, and from the three guides from EANM endorsed by SNM, two of them are 
therapy related, and one is diagnostic. Furthermore, the SNM has the following warning 
for the endorsed guidelines: “Applicable in the United States: The 
radiopharmaceutical(s) used for the diagnostic and therapeutic procedure(s) addressed 
in this guideline/guidance document is/are not approved by the Food and Drug 
Administration (FDA) in the United States. Therefore in the United States, these 
procedures should be performed only by physicians holding an FDA-approved 
Investigational New Drug (IND) application for the radiopharmaceutical.” This 
indicates that the practices that they endorse are not routinely procedures for the type of 
illness for which these procedures are prescribed in Europe. Additionally, the three 
guidelines were published by EANM in 2006, 2008 and 2010, but they were endorsed by 
SNM only in 2012. 
EANM also has a warning for the SNM guidelines they endorse, which states 
“EANM endorses these guidelines. Dosage recommendations should be taken in the 




international legal or regulatory provisions. The use of administered activities as 
reported in the EANM dosage card is suggested.” EANM doesn’t have a date for the 
endorsement of the SNM guidelines that were published in 2010. The warning messages 
between the two organizations are very different, and provide evidence for the 
differences in implementation between the regions. 
Table 9 describes when the guidelines were published by type of guideline. It is 
easy to see that the two guidelines for therapy from the SNM were published nine years 
apart, of difference while the EANM has been publishing therapy guidelines since 2002 
in a very regular manner. EANM has a peak in the publication of therapies in 2008 with 4 
publications, and a peak in the publication of diagnostic guidelines in 2009, with 11. The 
publications regarding diagnostic images from the SNM are continuously distributed in 
time, with a peak in 2009-2010. There is a great difference in the production of therapy 
guidelines between the two regions, but much less difference in the guidelines for 
diagnostic images. In the case of the general topics, it seems that it is a more recent 
preoccupation for EANM, while SNM has had this type of guideline for a longer time. 
There seems to be an unusual incentive in 2009 for the EANM because the production of 
diagnostic practice guidelines has a peak. 
 From this table is also clear that the high level of publication of EANM is not 
from a single time period, it is something that has been evolving, and the 13 guidelines 
for radionuclide therapy they have are the collection of knowledge over the years. This is 
an evidence of more and earlier implementation of radionuclide therapy techniques. For 
EANM the years of low production of therapy guidelines are years of low production in 




therapeutic guidelines. Based on the disclaimers on the endorsed guidelines, this lack of 
incentive to create their own guidelines is based on the fact that many of the drugs needed 
for the therapies are not approved, or are still under study by FDA. 














1999 0 0 0 0 0 2 
2000 0 0 0 0 2 0 
2001 0 0 0 0 0 1 
2002 1 0 0 1 2 2 
2003 1 1 0 1 3 4 
2004 0 0 0 0 0 4 
2005 0 0 0 0 1 0 
2006 1 0 0 0 1 4 
2007 1 0 1 1 2 0 
2008 4 0 1 0 1 2 
2009 0 0 0 0 11 8 
2010 2 0 4 2 6 7 
2011 1 0 0 1 2 3 
2012 0 1 1 1 1 3 
2013 2 0 1 0 0 0 
 
Summarizing up to this point, the US was the first to move to publish practice 
guidelines; however, most of their publications are focused on diagnostic procedures. The 
EU on the other hand, has been working in radionuclide therapies for a little longer than 
the US, but it has published a lot more guidelines related to this topic, which suggest that 
the EU has implemented radionuclide therapy technology more fully. In order to check if 
the guidelines were not only different in the type of procedure (diagnostic, therapy or 
general), but in the radionuclide material involved in the procedure, I analyzed the 




In order to find the radionuclides mentioned in each guideline, the eleven 
radionuclides of interest were searched among the guidelines with the “word search” 
function of Nvivo. Each search found where in the documents the radionuclides were 
mentioned. The selection of the radionuclides of interest was based on the previous 
exploration of the documents and the query of frequency of words (also run in Nvivo) to 
find what isotopes were mentioned in general. The search was done by the isotope but not 
by the radiopharmaceutical product, so it is possible that the regions are using the same 
isotope with different ligand/molecules for different purposes. Table 10 shows the 11 
isotopes used in the searches and the number of practice guidelines in each region that 
mention each isotope. From the table it is easy to notice that there are three isotopes that 
are not mentioned in any of the SNM guidelines, while EANM mentions all the isotopes 
at least once. The only isotope that the SNM mentions in more guidelines than EANM is 
Tc-99m, the most traditional isotope for nuclear medicine diagnostic images. 
Table 10: Isotopes in EANM and SNM Guidelines 
Isotope EU US 
 I-124/123 18 8 
 I-131 20 16 
In-111 26 20 
 Lu-177 3 0 
 P-32 1 1 
 Re-186 4 0 
 Sm-153 3 2 
 Sr-89 3 3 
 Tc-99m 24 31 
 Y-90 7 0 
F-18 11 6 
There is not only a diference in the number of guidelines that use radioisotopes, 
which is expected up to some point because EANM has more guidelines in general than  




types of practice guidelines the isotopes are mentioned. The isotopes that are not 
mentioned in any of the SNM guidelines (Lu-177, Re-186, and Y-90) are mentioned 
mostly in radionuclide therapy guidelines of the EANM. The isotopes that are more often 
mentioned in SNM guidelines (Tc-99m, In-111, and I-131) are mainly mentioned in 
relation to diagnostic images, although I-131 is one of the most comon and traditional 
isotopes used for thyroid therapies. One of the guidelines for therapy with I-131, “EANM 
procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy,” is 
endorsed by SNM and was published for the first time by EANM in 2003, and secondly 
in 2008, but was endorsed by SNM in 2012. The active ingredient in this therapy is Meta-
iodobenzylguanidine, or Iobenguane; Iobenguane was approved by the FDA in 1994, but 
it is currently discontinued. Meta-iodobenzylguanidine does not appear in the approved 
drugs dataset of the FDA (FDA, n.d.-a). The lack of clarity in the status of this therapy 
may create confusion for the new professionals trying to start their careers in this field, 
and for patients looking for information on these types of resources, and this may 
contribute to the delay in the time of implementation of radionuclide therapy techniques. 
Table 11: Mention of the different isotopes in the EANM and SNM guidelines 
	  
Diagnostic	   Therapy	   General	  
	  
EU	   US	   EU	   US	   EU	   US	  
	  F-­‐18	   10	   5	   0	   1	   1	   0	  
	  I-­‐124-­‐123	   11	   6	   6	   1	   1	   1	  
	  I-­‐131	   8	   12	   8	   2	   4	   3	  
	  In-­‐111	   14	   17	   8	   1	   4	   2	  
	  Lu-­‐177	   1	   0	   2	   0	   0	   0	  
	  P-­‐32	   0	   0	   1	   1	   0	   0	  
	  Re-­‐186	   1	   0	   3	   0	   0	   0	  
Sm-­‐153	   1	   0	   2	   2	   0	   0	  
Sr-­‐89	   1	   1	   2	   2	   0	   0	  
Tc-­‐99m	   20	   29	   2	   0	   2	   2	  





Another example of these differences is in one  of the 2011 SNM guidelines that 
mentions I-123, stating that “…this agent [123I-ioflupane] has shown efficacy for 
detecting degeneration of the dopaminergic nigrostriatal pathway, allowing better 
separation of patients with essential tremor from those with presynaptic Parkinsonian 
syndromes, as well as differentiating between some causes of parkinsonism.” Later in 
the same document they say that “123I-ioflupane (123I-FP-CIT) is a SPECT tracer, 
licensed by the European Medicines Agency and available in Europe since 2000. In the 
United States, 123I-ioflupane was approved by the Food and Drug Administration on 
January 2011 and is commercially available (22). This guideline covers the indications, 
technical aspects, interpretation, and reporting of DaT SPECT scans with 123I-ioflupane 
and considers the work of the European Association of Nuclear Medicine (23)” (Djang et 
al., 2012). With these statements the SNM acknowledges the benefits of this therapeuthic 
technique, and the delay in its implementation in the US. 
 Another good example is the Y-90 iosotpe. Although there are no guidelines from 
SNM that mention it, they have endorsed one that mentions this isotope. The guideline 
was published in 2006 by EANM. The summary of the guideline explains the success of 
these therapies, and the experience that they have had with it. “EMEA [European 
Medicines Agency] has approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin®, in 
Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ 
follicular B- cell non-Hodgkin´s lymphoma (NHL) in January 2004. The number of 
European nuclear medicine departments using Zevalin® is continuously increasing, 
since the therapy is often considered successful” (Giammarile, Lassmann, Oyen, & 




endorse, this procedure hasn’t been approved by the FDA. Nevertheless, FDA has 
approved Zevalin® since 2002, as shown in the database of approved drugs (FDA, n.d.-
b). Once again, the information between the guidelines, the disclaimers, and what FDA 
approves is conflicting. 
As a final example of the difference between the fields, the guideline published in 
collaboration among EANM, SNM and IAEA is for neuroendocrine tumor therapy. This 
guideline is not published on the SNM website, and mentions two of the isotopes that 
aren’t present in other SNM guidelines. The introduction mentions that 
 “[p]eptide receptor radionuclide therapy (PRRNT) is a molecularly 
targeted radiation therapy involving the systemic administration of a 
radiolabelled peptide designed to target with high affinity and 
specificity receptors overexpressed on tumours. PRRNT employing the 
radiotagged somatostatin receptor agonists 90Y-DOTATOC([90Y-
DOTA0,Tyr3]-octreotide) or 177Lu-DOTATATE ([177Lu-
DOTA0,Tyr3,Thr8]-octreotide or [177Lu-DOTA0,Tyr3]-octreotate) 
have been successfully used for the past 15 years to target metastatic 
or inoperable neuroendocrine tumours expressing the somatostatin 
receptor.” 
Later in the same introduction they mention the regulatory issues with a special section 
for US. 
“The radiopharmaceuticals used for the diagnostic and therapeutic 
procedures addressed in this guidance document are not approved by 
the Food and Drug Administration (FDA) in the USA. Therefore in the 
USA these procedures should be performed only by physicians enrolled 
in an investigational protocol pursuant to a valid Investigational New 
Drug application or Radioactive Drug Research Committee approval 
and under the purview of an appropriate institutional review board.” 
This particular example is interesting because it is about the same  technology 
mentioned in the paper “Radiopeptide Imaging and Therapy in the United States” by 




“[t]he regulatory requirements in the United States also restrict access 
to several radionuclide peptides that are being used as clinical tools in 
a growing number of institutions across Europe. This issue is 
potentially critical for patients who may benefit from PRRT and need to 
travel to Europe for this treatment. Future attempts to balance the 
effort in the field with appropriate clinical trials are important so that 
at least some of these remarkable agents can be made available to 
patients in the United States.” 
This paper received a response from Peeyush Bhargava and Ebrahim S 
Delpassand in May, 2012 saying that they have two clinical trials going on in this topic 
since 2010 in the US. The differences in information, plus the fact that the joint guideline 
says that this practice has been going on for more than 15 years, shows how the 
information and knowledge flows are dissimilar within each region and between regions.  
While the European guidelines are clear about the approval situation of new 
drugs, and there are no guidelines for the use of non-approved radiopharmaceuticals, the 
US case is very different with several guidelines that overlap in topic, and special 
miscommunications regarding the approval status of the drugs. The communication 
factor among professionals in a field was a particularly important factor for the 
Canandian study of breast cancer tehcniques by Wright about technology implementation 
(Wright et al., 2011). It is difficult to implement new technologies if there is no good 
communication among professionals. From the results of the therapy guidelines analysis, 
and the papers review in the topic the communication among professionals may be one of 
the reasons for variations in the time of implementation of new technologies in the 
radionuclide therapy field.  
Up to here, I have presented the results of the analysis of the practice guidelines 
of the European and American professional soceties of nuclear medicine in time and 




guidelines that cover different types of radionuclide therapy, although the US started 
publishing procedures before Europe did. Because Europe has implemented more 
variations of radionuclide therapies, and having in mind the endoresed guidelines, it is 
possible to say that the EU has implemented these technologies more fully than the US. 
In order to confirm and support these results, the next section presents the results of the 
bibliometric analysis. 
Bibliometric Analysis of Case Reports 
 
The results found in the bibliometric analysis reinforce those previously shown in 
practice guidelines. Europe has implemented radionuclide therapies before and more than 
the US. For the bibliometric analysis four databases were consulted: Pubmed, Medline, 
Biosis Preview, and ISI Web of Knowledge with a total of 103 unique publications. Of 
these publications, 64 are published in Europe, meaning that the country or country of 
affiliation of the bilbiometric data is a European Union country. There are 26 publications 
that are from US, or have some US affiliation. There are 2 publications that are Europe 
and US affiliated, both from the same authors. Figure 12 shows how the first publication 
that complies with the keyword search in Europe appeared almost ten years before the 
first case report from  the US. There is also a general increase of these publications since 
2000. There are a couple of years when the EU did not publish case reports; however, 
there are eight years when the US did not publish case reports on radionuclide therapies. 
In 2002 the US has more publications in a diverse line of topics whithin radionuclide 
therapy, while the peak year of publications for the EU was 2012, and from the nine EU 
publications in that year seven were focused in neuroendocrine cancers and peptide 




 Figure 12 Bibliometric Results 
 
It is clear that the time of implementation of radionuclide therapies is different 
between the US and the EU. The EU has more practice guidelines about these techniques, 
and more case reports published on radionuclide therapy techniques. Additionally to 
these differences in implementation of new technologies in radionuclide therapies, there 
are differences in the policies and regulations on NM that may account for the 
implementation  dissimilarity.  
There are three main policy fields whose the differences may impact the 
difference in time of implementation of radionuclide techolgies in NM. These are the 
difference in education policies for NM specialists, the production of isotopes for medical 
use, and the regulations for approval of new radiopharmaceutical drugs. The education 
policies are important because NM, and specially radionuclide therapies, are technologies 
that need to be implemented by a highly educated team in different areas such as 
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radionuclide tharapies is also a determinant of the existence of the technology in a region; 
without a good suppply of radioisotopes there is no posibility of implementation of the 
technique. Finally, the lack of clarity in the procedures for the approval of 
radiopharmaceutical drugs delays the time of implementation of the technology and 
prevents innovation and knowledge transfer in this area. In the last chapter I will analyze 
in detail how each of these policy fields may affect the implementation of radionuclide 





CHAPTER 5 – DISCUSSION AND CONCLUSIONS 
 
 This project started with the question: Are radionuclide therapies implemented 
before in the EU than the US? In order to answer that, I assumed that the practice 
guidelines and publications of radionuclide therapy case reports were evidence of 
implementation; therefore, I am able to conclude that the EU has implemented 
radionuclide therapies earlier and more fully than the US. This result was followed by the 
second question: What differences are there in policies relevant to nuclear medicine 
between the US and the EU? I was able to identify key international organizations that 
may affect the policy environment in nuclear medicine as well as key differences in the 
policy arena between the EU and the US. These key differences are in education, the 
supply of radioactive materials, and radiopharmaceutical drug approval policies. Now I 
will discuss the answers to the last two questions of this project: To what extent, if at all, 
can the differences in policies explain differences in the time of implementation of 
radionuclide therapies? And what other factors might explain these differences in the 
time of implementation?  
The Education Barrier 
 
First, education is very important in the field of NM because a well-educated staff 
not only assures the safety of the service, but also is up to date with the field research and 
techniques. As I showed in chapter 2, NM is a very specialized field of medicine that 
needs the support of very specialized professionals in physics and chemistry, as well as 
trained technicians and nurses that need to know about radiation protection in order to 
have a safe practice. The main difference between training in nuclear medicine in the US 




US don’t have all the same background. In US you can be a nuclear radiologist and never 
have to do a therapy or be a nuclear medicine specialist and work in diagnosis and 
therapy. The editorial by H. Ziessman in the Journal of Nuclear Medicine in 2012 
(Ziessman, 2012) explains the difference between the Nuclear Medicine Residency and 
the Nuclear Radiology Fellowship. The first one is accredited by the American Board of 
Nuclear Medicine while the fellowship one is a certification in Nuclear Radiology. 
Although he mentions that the number of candidates for the residency is an average of 55 
vs 5 from the fellowship, the fact that there are two professional organizations competing 
for students under different requirements is not positive for the field. One of the main 
differences in the standards between the fellowship and the residency used to be the 
presence of “radionuclide therapies” in the standards of education; it used to be a 
requirement for the residency, but not for the fellowship, but since 2012 the fellowship is 
trying to incorporate the therapies in to the curriculum. The lack of knowledge of some 
nuclear medicine specialists about radionuclide therapy techniques may explain the 
increased focus of US professionals on diagnostic techniques and PET, and the late 
implementation in therapy. The EU, on the other hand, has a proposed syllabus in NM 
that is intended to privide standardization in the education of physicians, and that 
contains a broader spectrum of the field including radionuclide therapies (Cuocolo, 
Milcinski, & Bischof Delaloye, 2008; Prigent, Huic, & Costa, 2012). 
In addition to the education of medical practitioners, the education and 
certifications required in the medical physics and radiopharmacy professions may 
influence the development of the field of NM. In the EU the presence of a medical 




EURATOM. In the US the principal focus of the medical physicist is radiotherapy, and 
regulation is not consistent nationwide, as these certifications vary at the state level. 
Additionally, there are very few radiopharmacy programs in the US. The lack of these 
professionals in the NM practices means they don’t bring knowledge and innovation, 
which interferes with the development and implementation of radionuclide therapies in 
the US. 
The Market Failure 
 
The lack of supply of radioactive isotopes, the primary material for radionuclide 
therapies, interferes with the implementation of this technique. The production of the 
radioisotopes used in nuclear medicine is done in nuclear reactors, and the supply of 
these isotopes is often subsidized by governments because of the high cost and risk 
associated with their production. However, there is not enough research on how this 
market works, and on less expensive and risky ways to produce radioisotopes. Having in 
mind that US technetium depends on a Canadian nuclear reactor that may be 
decommissioned in few years, and that US research reactors produce only small 
quantities of radioactive material, it is difficult to imagine what the future of this field in 
the US will be if there is not enough supply. The bill S. 99 (112th): American Medical 
Isotopes Production Act of 2011 was proposed as a solution to this problem, but died 
after passing the Senate in 2011. Meanwhile, Canada has invested in R&D to solve the 
technetium availability problem and as a result a PhD researched and found a way to 
produced technetium in a cyclotron (Gagnon, 2012), but it may take years until this 
technology is available, and it doesn’t solve the problem of producing radionuclides for 




the interest of NM professionals to PET applications where the isotope production can be 
controlled easily because they can be produced in hospitals and at the levels that are 
convenient for each institution. Moreover, the market model works better in this part of 
the NM practice, because the technology is cheaper (compared with the construction of a 
nuclear reactor), the risk is lower, and private investors such as clinics are able to 
participate. 
There are more nuclear reactors in the EU that produce radioisotopes for medical 
use, and the uranium market for energy and isotope production is controlled in order to 
ensure availability in the participant countries. Additionally, in the EU the different 
approach that the countries take toward nuclear reactor scenario is less likely to affect the 
country supply of radioactive material because in a region with a great variety of 
countries there are also a great variety of approaches to the “nuclear reactor” problem.  
The issue of supply of radioactive materials for NM is a complicated issue and 
deserves a lot of study and attention, and besides the OECD-NEA there are not a lot of 
efforts to study the medical radioisotope market.  
The Regulatory Path Complications 
 
The US not only needs to deal with the lack of supply of radioisotopes for 
therapeutic use, but with a lack of clarity in the FDA about the path for approval of 
radionuclide therapies, and this may slow down the implementation of radionuclide 
therapy technologies in the US. The role of the FDA and its policies on radionuclide 
therapies is continuously mentioned in the publications about nuclear medicine from the 
Academies of Science and other academic papers, which often make reference to the lack 




Contrary to the US, the EU has a unified system of approval for 
radiopharmaceutical drugs, and the professional society provides a route map for 
researchers that want to make a drug available in the EU. These types of tools are 
invaluable for the transfer of technology and knowledge from the lab to the medical 
center, and they facilitate the implementation of new technologies. 
Other Possible Explanations 
 
One thing that caught my attention during the development of this project is that 
the US professional field showed signals of problems in communication and coordination 
within the field. This may not only explain the lack of implementation of radionuclide 
technology, but also account for some of the policy issues, because if there are conflicts 
among the professionals in the field it is difficult to find the coalitions that would move 
forward the policies needed for the development of the field. This is evident in the 
confusing information about clinical trials, approved drugs, paths for drug approval, and 
overlapping practice guidelines. All these conflicts in information impede the flow of 
knowledge among practitioners, scientists, and patients.  
If there is a lack of communication among professionals, as the one perceived in 
the literature review, this would not only slow down the implementation of new 
technologies, but would prevent professionals in NM from coming together as a field to 
shape the policies that affect them. This is especially evident with the FDA, because it is 
still complicated to find and understand their policies on radionuclide materials, and in 
the lack of solutions for the production of radioactive isotopes in US since the bill S. 99 
(112th): American Medical Isotopes Production Act of 2011 didn’t pass and nothing else 




The other problem in communication and coordination among professionals is the 
relationship between Radiology and Nuclear Medicine in the US. Ziessman, in an 
editorial mentioned above, finishes by saying that 
“Radiology leadership has never fully accepted nuclear medicine as an 
independent specialty and considers it a subspecialty of radiology. 
However, the ACGME and ABMS consider nuclear medicine a primary 
specialty. It is time for radiology leadership to begin to work together 
with nuclear medicine to devise the best educational experience to train 
future nuclear medicine physicians and to certify them.” 
 
 With this statement, he recognizes that there is a problem with the two fields 
trying to complete, and part of the result of that competition may be the lack of 
implementation of radionuclide therapies in US. 
The poor communication among professionals in the field may be playing a 
bigger role that it appears in my documentation analysis. There are other methods to 
measure and explore that, which are not part of this project, but which may be of interest 
for the future. 
Conclusion 
 
This project aimed to explain the particularities of nuclear medicine, its role in the 
medical field, and more specifically the use of radionuclide therapies in nuclear medicine. 
I found that there are important differences in time and types of implementation of 
radionuclide therapies between the EU and the US, and this was demonstrated through 
the date of publication and content of practice guidelines and case report publications. 
Europe has more practice guidelines in radionuclide therapies and has published them 
more often, while the US started publishing earlier but has only written two practice 




The variations in implementation between the regions were then analyzed from 
the policy aspect and I found three main policy fields that may be affecting the 
implementation of these techniques in US. First, the variety of standards in nuclear 
medicine education; second, the unreliable supply of radionuclide material in the US, and 
third the confusing regulatory path for radiopharmaceuticals for therapies. As an 
additional explanation, I proposed the poor communication flow among professionals in 
the nuclear medicine field, which was evident in the documentation analysis but would 
need to be explored further in the future.  
It is important to continue exploring why nuclear medicine therapies are 
implemented slowly in the US, and to make an effort to standardize education and 
credentials for the different professionals involved in this field. It is also very important 
to solve the supply problem of radionuclide materials in the US. Without policies to 
incentivize the production of radioisotopes for medical use and/or the use of Low 
Enriched Uranium or other techniques for the production of nuclear medicine supplies, 
there is going to be a bigger delay in the implementation of radionuclide therapies. 
Moreover, without policies that confront this problem the whole practice may be at risk, 
and those most affected will be the patients that benefit from this practice. Finally, a clear 
path for radionuclide drug approval by FDA will benefit the knowledge transfer process 
from the lab to the practice in nuclear medicine.  
In conclusion, radionuclide therapy is a technology whose implementation is 
behind in the US compared with the EU, and this is due to problems in the 
standardization of education, lack of supply of radioactive materials, and confusing 




the practice will keep being behind in radionuclide therapy and potentially in other parts 





APPENDIX A: List of Practice Guidelines 
 
SNM Practice Guidelines  Date Approved 
   
Cardiac   
Procedure Guideline for Myocardial Perfusion Imaging  9/1/08 
Society of Nuclear Medicine Procedure Guideline for Gated 
Equilibrium Radionuclide Ventriculography 6/15/02 
Endocrine   
SNM Practice Guideline for Parathyroid Scintigraphy  9/17/11 
Society of Nuclear Medicine Procedure Guideline for Thyroid 
Scintigraphy 9/10/06 
Society of Nuclear Medicine Procedure Guideline for 
Scintigraphy for Differentiated Papillary and Follicular 
Thyroid Cancer 
9/5/06 
Society of Nuclear Medicine Procedure Guideline for Thyroid 
Uptake Measurement 9/5/06 
Gastrointestinal   
SNM Practice Guideline for Hepatobiliary Scintigraphy 6/4/10 
Procedure Guideline for Adult Solid-Meal Gastric-Emptying 
Study 2/8/09 
Society of Nuclear Medicine Procedure Guideline for Hepatic 
and Splenic Imaging  6/20/03 
General   
SNM/EANM Guideline for Guideline Development 6.0 6/8/12 
Clinical Performance Standards FOR THE NUCLEAR 
MEDICINE TECHNOLOGIST (Revision 2011) 5/11/11 
THE SNM PROCEDURE GUIDELINE FOR GENERAL 
IMAGING 6.0  9/12/10 
Procedure Guideline for the Use of Radiopharmaceuticals 2/7/08 
Society of Nuclear Medicine Procedure Guideline for 
Diagnosis of Renovascular Hypertension 6/20/03 
Society of Nuclear Medicine Procedure Guideline for 
Telenuclear Medicine 6/15/02 
Infection   
Society of Nuclear Medicine Procedure Guideline for Gallium 
Scintigraphy in Inflammation 6/2/04 
Society of Nuclear Medicine Procedure Guideline for 99mTc-
Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for 





Society of Nuclear Medicine Procedure Guideline for 111In-
Leukocyte Scintigraphy for Suspected Infection/Inflammation  6/2/04 
Musculoskeletal   
SNM Practice Guideline for Sodium 18F-Fluoride PET/CT 
Bone Scans 12/2/10 
Society of Nuclear Medicine Procedure Guideline for Bone 
Scintigraphy 6/20/03 
Neurology   
SNM Practice Guideline for Brain Death Scintigraphy 6/8/12 
SNM Practice Guideline for Dopamine Transporter Imaging 
with 123I-Ioflupane SPECT 10/26/11 
Society of Nuclear Medicine Procedure Guideline for FDG 
PET Brain Imaging 2/8/09 
Procedure Guideline for Brain Perfusion SPECT Using 
99mTc Radiopharmaceuticals 2/8/09 
Oncology   
The SNM Practice Guideline for Therapy of Thyroid Disease 
with 131I 6/8/12 
The SNM Practice Guideline for Somatostatin Receptor 
Scintigraphy 7/19/11 
SNM Practice Guideline for Breast Scintigraphy with Breast-
Specific g-Cameras 6/4/10 
Procedure Guideline for SPECT/CT Imaging 4/3/06 
Procedure Guideline for Tumor Imaging with 18F-FDG 
PET/CT 2/11/06 
Society of Nuclear Medicine Procedure Guideline for Breast 
Scintigraphy 6/2/04 
Society of Nuclear Medicine Procedure Guideline for 
Palliative Treatment of Painful Bone Metastases 1/25/03 
Society of Nuclear Medicine Procedure Guideline for 
Lymphoscintigraphy and the Use of Intraoperative Gamma 
Probe for Sentinel Lymph Node Localization in Melanoma of 
Intermediate Thickness 
6/15/02 
Pediatric   
Pediatric Radiopharmaceutical Administered Doses: 2010 
North American Consensus Guidelines 10/1/10 
Procedure Guideline for Diuretic Renography in Children 9/1/08 
Society of Nuclear Medicine Procedure Guideline for Renal 
Cortical Scintigraphy in Children 6/20/03 
Society of Nuclear Medicine Procedure Guideline for 




Society of Nuclear Medicine Procedure Guideline for 
Radionuclide Cystography in Children 1/25/03 
Pulmonary   
SNM Practice Guideline for Lung Scintigraphy 7/19/11 
EANM Guidelines   
EANM procedure guidelines for 131I-meta-
iodobenzylguanidine (131I-mIBG) therapy 9/22/12 
131I/123I-Metaiodobenzylguanidine (mIBG) Scintigraphy – 
Procedures Guidelines For Tumour Imaging  3/20/12 
EANM procedure guideline of radio-immunotherapy for B-
cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan 
(Zevalin®) 
3/20/12 
Collaborative Guidelines   
ACR–SNM TECHNICAL STANDARD FOR DIAGNOSTIC 
PROCEDURES USING RADIOPHARMACEUTICALS  2011 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF CARDIAC SCINTIGRAPHY 2009 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF GASTROINTESTINAL 
SCINTIGRAPHY  
2010 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF SCINTIGRAPHY FOR 
INFLAMMATION AND INFECTION 
2009 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF LIVER AND SPLEEN 
SCINTIGRAPHY  
2010 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF PARATHYROID SCINTIGRAPHY 2009 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF PULMONARY SCINTIGRAPHY IN 
ADULTS AND CHILDREN 
2009 
ACR–SPR–SNM PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF ADULT AND PEDIATRIC 
RADIONUCLIDE CYSTOGRAPHY 
2010 
ACR–SNM–SPR PRACTICE GUIDELINE FOR THE 
PERFORMANCE OF THYROID SCINTIGRAPHY AND 
UPTAKE MEASUREMENTS 
2009 
Pediatric Radiopharmaceutical Administered Doses: 2010 
North American Consensus Guidelines 10/26/10 
Retired Guidelines   
Society of Nuclear Medicine Procedure Guideline for Gallium 
Scintigraphy in the Evaluation of Malignant Disease 6/23/01 
Society of Nuclear Medicine Procedure Guideline for Tumor 




Society of Nuclear Medicine Procedure Guideline for 





EANM Date Approved 
Cardiology  
Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint 
position statement by the European Association of Nuclear 
Medicine (EANM), the European Society of Cardiac 
Radiology (ESCR) and the European Council of Nuclear 
Cardiology (ECNC) 
2011 
EANM/ESC guidelines for radionuclide imaging of cardiac 
function 2008 
EANM/ESC procedural guidelines for myocardial perfusion 
imaging in nuclear cardiology 2005 
Dosimetry  
EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-
Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid 
diseases 
2013 
EANM Dosimetry Committee Series on Standard Operational 
Procedures for Pre-Therapeutic Dosimetry 
II. Dosimetry prior to radioiodine therapy of benign thyroid 
diseases 
2013 
EANM Dosimetry Committee guidance document: good 
practice of clinical dosimetry reporting 2010 
EANM Dosimetry Committee guidelines for bone marrow and 
whole-body dosimetry 2010 
EANM Dosimetry Committee series on standard operational 
procedures for pre-therapeutic dosimetry I: blood and bone 
marrow dosimetry in differentiated thyroid cancer therapy 
2008 
Drug Development  
Guideline to regulations for radiopharmaceuticals in early 
phase clinical trials in the EU 2008 
Inflammation/Infection  




Guidelines for the labelling of leucocytes with 99mTc-
HMPAO 2010 
Neuroimaging  
EANM procedure guidelines for PET brain imaging using 
[18F]FDG, version 2 2009 
EANM procedure guidelines for brain neurotransmission 
SPECT/PET using dopamine D2 receptor ligands, version 2 2009 
EANM procedure guidelines for brain neurotransmission 
SPECT using 123I-labelled dopamine transporter 
ligands,version 2 
2009 
EANM procedure guideline for brain perfusion SPECT using 
99mTc-labelled radiopharmaceuticals, version 2 2009 
EANM Procedure GuidelinesforBrain Tumour Imaging 
usingLabelled Amino Acid Analogues 2006 
Oncology  
EANM 2012 guidelines for radionuclide imaging of 
phaeochromocytoma and paraganglioma 2012 
Integration of FDG-PET/CT into external beam radiation 
therapy planning 2012 
111In-pentetreotide scintigraphy: procedure guidelines for 
tumour imaging 2010 
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: 
procedure guidelines for tumour imaging 2010 
Procedure guidelines for PET/CT tumour imaging with 68Ga-
DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-
DOTA-NOC, 68Ga-DOTA-TATE 
2010 
PET in radiotherapy planning: Particularly exquisite test or 
pending and experimental tool? 2010 
EANM-EORTC general recommendations for sentinel node 
diagnostics in melanoma 2010 
Joint practice guidelines for radionuclide lymphoscintigraphy 






FDG PET and PET/CT: EANM procedure guidelines for 
tumour PET imaging: version 1.0 2009 
FDG PET and PET/CT: EANM procedure guidelines for 
tumour PET imaging: version 1.0-Presentation 2009 
Sentinel node in breast cancer procedural guidelines 2007 
67GA SCINTIGRAPHY PROCEDURE GUIDELINES FOR 
TUMOUR IMAGING 2003 
BONE SCINTIGRAPHY PROCEDURES GUIDELINES 
FOR TUMOUR IMAGING 2003 
BREAST SCINTIGRAPHY PROCEDURE GUIDELINES 
FOR TUMOUR IMAGING 2003 
Paediatrics  
Guidelines for standard and diuretic renogram in children 2011 
Guidelines for paediatric bone scanning with 99mTc-labelled 
radiopharmaceuticals and 18F-fluoride 2010 
GUIDELINES ON 99mTc-DMSA SCINTIGRAPHY IN 
CHILDREN 2009 
Guidelines for 18F-FDG PET and PET-CT imagingin 
paediatric oncology 2008 
Guidelines for lung scintigraphy in children 2007 
GUIDELINES FOR DIRECT RADIONUCLIDE 
CYSTOGRAPHY IN CHILDREN 2002 
GUIDELINE FOR RADIOIODINATED MIBG 
SCINTIGRAPHY IN CHILDREN 2002 
GUIDELINES FOR GLOMERULAR FILTRATION RATE 
DETERMINATION IN CHILDREN 2000 
GUIDELINES FOR INDIRECT RADIONUCLIDE 
CYSTOGRAPHY 2000 
GUIDELINES FOR STANDARD AND DIURETIC 
RENOGRAM IN CHILDREN 2000 
Parathyroid  
2009 EANM parathyroid guidelines 2009 
Physics  




Routine quality control recommendations for nuclear medicine 
instrumentation 2010 
Curriculum for education and training of Medical Physicists in 
Nuclear Medicine 2012 
Pulmonary Embolism  
EANM guidelines for ventilation/perfusion scintigraphy Part 
1. Pulmonary imaging with ventilation/perfusion single photon 
emission tomography 
2009 
EANM guidelines for ventilation/perfusion scintigraphy Part 
2. Algorithms and clinical considerations for diagnosis of 
pulmonary emboli with V/PSPECT and MDCT 
2009 
Radionuclide Therapy  
EANM procedure guideline for the treatment of liver cancer 
and liver metastases with intra-arterial radioactive compounds 2011 
EANM procedure guidelines for therapy of benign thyroid 
disease 2010 
EANM procedure guidelines for 131I-meta-
iodobenzylguanidine (131I-mIBG) therapy 2008 
EANM procedure guideline for treatment of refractory 
metastatic bone pain 2008 
Guidelines for radioiodine therapy of differentiated thyroid 
cancer 2008 
EANM procedure guideline for 32P phosphate treatment of 
myeloproliferative diseases 2007 
EANM procedure guideline of radio-immunotherapy for B-
cell lymphoma with 90Y-radiolabeled ibritumomab tiuxetan 
(Zevalin®) 
2006 
EANM Procedure Guidelines for Radiosynovectomy 2002 
GUIDELINES FOR 131 I - ETHIODISED OIL [LIPIODOL] 
THERAPY 2002 
Radiopharmacy  
Guidance on current good radiopharmacy practice (cGRPP) 
for the small-scale preparation of radiopharmaceuticals 2010 
GUIDELINES ON CURRENT GOOD RADIOPHARMACY 






Collaboration in Guidelines  
SNM/EANM Guideline for Guideline Development 6.0* 2012 
SNMMI Guidelines - endorsement by EANM  
SNM Practice Guideline for Sodium 18F-Fluoride PET/CT 
Bone Scans 2010 
SNM Practice Guideline for Breast Scintigraphy with Breast-
Specific g-Cameras 2010 
Joint Guidelines  
The joint IAEA, EANM, and SNMMI practical guidance on 
peptide receptor radionuclide therapy (PRRNT) in 
neuroendocrine tumours 
2013 
Technologist Guidelines  
Principles and Practice of PET/CT 2010 
Advanced Performance and Responsibility Guidelines for the 
Nuclear Medicine Technologist. 2001 
Patient information leaflets. 2001 
Competences for the European Nuclear Medicine Technologist 1998 







IAEA LIST OF DOCUMENTS FOR NUCLEAR MEDICINE 
Human Health Series 
Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides 
Human Health Series No.8 Publication  1416 
Quality Assurance for SPECT Systems 
Human Health Series No.6 Publication  1394 
Quality Assurance for PET and PET/CT Systems 
Human Health Series No.1 Publication  1393 
Appropriate use of FDG-PET 
for the Management of Cancer Patients 
Human Health Series No.9 Publication  1438 
Planning a Clinical PET Centre 
Human Health Series No.11 Publication  1457 
Atlas of Bone Scintigraphy in the Developing Paediatric Skeleton: The Normal Skeleton, 
Variants and Pitfalls 
Human Health Series No.16 Publication  1491  
Quality Assurance Programme for Screen Film Mammography 
Human Health Series No.2 Publication  1381 
Comprehensive Clinical Audits of Diagnostic Radiology Practices: A Tool for Quality 
Improvement 
Human Health Series No.4  Publication  1425 
Comprehensive Clinical Audits of Diagnostic Radiology Practices: A Tool for Quality 
Improvement 
Human Health Series No.17  Publication  1482  
 
Human Health Reports 
Implementation of the International Code of Practice on Dosimetry in Diagnostic Radiology 
Technical Reports Series No. 457: Review of Testing Results Publication  1498 
 
Books and Publications 
IAEA Quality Control Atlas for Scintillation Camera Systems - 2003 
Publication  1141 




Publication  1198 
Operational Guidance on Hospital Radiopharmacy A Safe and Effective Approach - 2008 
Publication  1342 
Quality Management Audits in Nuclear Medicine Practices - 2008 
Publication  1371  
Strategies for Clinical Implementation and Quality Management of PET Tracers - 2009 
Publication  1344 
 
Training Course Series 
Clinical Training of Medical Physicists Specializing In Nuclear Medicine 
Training Course Series No. 50 
Competency Based Hospital Radiopharmacy Training 
Training Course Series No. 39 
 
IAEA Technical Documents (TECDOC) 
A Guide to Clinical PET in Oncology: Improving Clinical Management of Cancer Patients 
IAEA TECDOC-1605 
Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System  
IAEA TECDOC-1597 
Criteria for Palliation of Bone Metastases - Clinical Applications 
IAEA TECDOC CD-1549  
Development of Kits for 99mTc Radiopharmaceuticals for Infection Imaging 
IAEA TECDOC-1414 
Nuclear Medicine in Thyroid Cancer Management: A Practical Approach 
IAEA TECDOC-1608 
Strategy and Methodology for Radioactive Waste Characterization 
IAEA TECDOC-1537 
The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment  
IAEA TECDOC-1603 
Radioisotope Handling Facilities and Automation of 
Radioisotope Production 
IAEA TECDOC-1430 
Development of Radioimmunometric Assays and 






Radioisotopes and Radiopharmaceuticals Series 
Technetium-99m Radiopharmaceuticals: Status and Trends 
Publication  1405 
 
Nuclear Security Series 
Security in the Transport of Radioactive Material 
IAEA Nuclear Security Series No.  9 Publication 1348 
Security of Radioactive Sources 
IAEA Nuclear Security Series No.  11 Publication 1387 
 
Safety Standards Series 
International Basic Safety Standards for Protection against Ionizing Radiation and for the 
Safety of Radiation Sources (CD-ROM Edition, 2003) 
IAEA Safety Series No.  115/CD Publication 996  
Legal and Governmental Infrastructure for Nuclear, Radiation, Radioactive Waste and 
Transport Safety 
IAEA Safety Standards Series No.  GS-R-1 Publication 1093 
Governmental, Legal and Regulatory Framework for Safety General  - Safety Requirements 
Part  1. 
IAEA Safety Standards Series 1100 Subject Classification: 0614-Legal and governmental aspects 
 
Regulatory Control of Radiation Sources 
IAEA Safety Guide GS-G-1.5 Publication 1192 
 
Safety Report Series 
Release of Patients After Radionuclide Therapy 
Safety Reports Series No. 63 Publication 1417 
Applying Radiation Safety Standards in Nuclear Medicine 
Safety Reports Series No.  40 Publication 1207 
Optimization of Radiation Protection in the Control of Occupational Exposure   
Safety Reports Series No.  21 Publication 1118 




Safety Reports Series No.  60 Publication 1366 
Radiation Protection in Newer Medical Imaging Techniques: PET/CT 
Safety Reports Series No.  58 Publication 1343 
 
Technical Report Series 
Quality Assurance for Radioactive Measurement in Nuclear Medicine 
Technical Reports Series No.  454 
Technetium-99m Radiopharmaceuticals: Manufacture of Kits 
Technical Reports Series No.  466 
Comparative Evaluation of Therapeutic Radiopharmaceuticals 
Technical Reports Series No.  458 
Labelling of Small Biomolecules using Novel Technetium-99m Cores 
Technical Reports Series No.  459 
Therapeutic Radionuclide Generators: 90sr/90y and 188w/188re Generators 
Technical Reports Series No.  470 
Cyclotron Produced Radionuclides: Guidelines for Setting up a Facility 
Technical Reports Series No.  471 
Cyclotron Produced Radionuclides: Physical Characteristics and Production Methods 
Technical Reports Series No.  468 
Cyclotron Produced Radionuclides: Principles and Practice 
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